[{"article": "Those taking Jardiance had a 32 percent lower risk of dying from any cause, and a 35 percent lower rate of hospitalizations from heart failure.\n\u201cThis is the first diabetes therapy to show robust effect in reducing cardiovascular death. It really is big news,\u201d said Dr. Bernard Zinman, director of the Diabetes Centre at Mount Sinai Hospital in Toronto, who led the three-year study of 7,000 people.\n\u201cThis is a wonderful thing,\u201d said Dr. Jerome Tolbert of Mount Sinai Beth Israel Hospital in New York. He has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The initial version of this story includes only comments from Dr. Bernard Zinman, the lead investigator. The updated version of the story includes additional perspectives on the research, but neither version of the story makes it clear the the study was funded by\u00a0Boehringer Ingelheim and Eli Lilly, or that Dr Zinman and other co-authors disclosed financial relationships with Boehringer Ingelheim related to the study and outside of the study.", "answer": 0}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story just barely scores a Satisfactory rating on this one. It is clear that Merck & Co. is funding this research. A couple of sources are overtly linked to the company. A third, Dr. Stefan Zimmerman, appears to be independent, though he\u00a0wasn\u2019t quoted saying anything that helped illuminate the findings, instead he\u2019s quoted as saying \u201cRemember this day. It\u2019s a new day for lung cancer treatment.\u201d Some additional commentary from an oncologist or a patient advocate would likely have helped put the findings in perspective.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only non-peer-reviewed company-sponsored research was reported.\u00a0 No independent sources were cited. ", "answer": 0}, {"article": "A stroke occurs when a clot cuts off blood flow to parts of the brain. Those parts of the brain soon start to die. A drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted. But it would have been better if he\u2019d been quoted on the quality of the evidence.", "answer": 1}, {"article": "Xiaflex is an enzyme produced by a gangrene-causing bacterium, Clostridium histolyticum, which uses it to eat away the tissues of its victims. The enzyme, called collagenase, breaks down collagen, a major component of the body\u2019s connective tissue that is found in skin, tendons, cartilage and other organs.\nAuxilium and BioSpecifics hope that the half-century-old collagenase might eventually become as versatile as Botox, another bacterial product. They are looking at uses that range from loosening up immobile \u201cfrozen shoulders\u201d to eliminating fat bulges and cellulite.\nEd Wegman, the company\u2019s founder, did not live to see the F.D.A. approval, dying at age 87 in 2007. On Feb. 2, the day the drug was approved, one BioSpecifics director sent an e-mail message to the others saying, \u201cWell done. Hope Ed is looking on.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most of the sources in this story are affiliated in some way with organizations that will profit from the sale of Xiaflex. These conflicts are disclosed, however, and the story does offer some clinical perspective from a hand specialist who does not appear to be connected to\u00a0Xiaflex. \u00a0", "answer": 1}, {"article": "\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\nEvidence suggests it may not only be good for mind and body, but also for a long life\nThe evidence shows that playing golf regularly is associated with longevity and reducing the risk factors for heart disease/stroke. And it can boost older people's strength and balance.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is the second major weakness of this news release.\nIt\u2019s not mentioned that this \u201c2018 Consensus Statement on Golf and Health\u201d was funded by an unrestricted grant from the World Golf Foundation.\nTwo of the authors receive fees from the European Golf tour and one is the director of Golf Development at the Royal and Ancient Golf Club in St. Andrews, Scotland.", "answer": 0}, {"article": "Lung cancer is the leading cause of cancer death. The American Cancer Society (ACS) estimates that more than 224,000 Americans will be diagnosed with lung cancer this year, and more than 158,000 lung cancer patients will die\u2014that translates to 433 lung cancer deaths per day in the United States.\n\u201cThe rapid normalization of almost all of the four compounds after surgery provides strong evidence that they are directly produced by the tumor environment,\u201d said Dr. Schumer. \u201cThis study confirms that the technology is accurate.\u201d\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel. \u201cThe technology is pretty robust. Our next step is getting approval from the FDA.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release earns a satisfactory here for providing both funding sources and pointing out that three of the seven researchers have ties to a medical equipment company which deals with breath analysis. The information, however, lies at the end of the story in a portion commonly referred to as \u201cboilerplate\u201d information, which readers often ignore. Incorporating such info into the body of the release better serves readers.", "answer": 1}, {"article": " For more fitness, food and wellness news, \u201clike\u201d our Facebook page.\nAn experiment with 24 healthy volunteers found that compared with consuming glucose, consuming fructose \u2014 the sugar found in fruits, honey and corn syrup \u2014 resulted in more activity in the brain\u2019s reward regions, increased responses to images of food and a tendency to choose eating a high-calorie food over a future monetary reward.\n\u201cInsulin is released when we consume glucose,\u201d she said. \u201cThe pancreas secretes insulin, and insulin drives glucose into cells so that it can be used for energy. But it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only one source, and clearly notes that the source is an author of the relevant study. However, the story lacked an independent expert to put the work in context.\u00a0This story badly needed that context to give us a sense of how important this work might be, and what similar work may have been done in this area. For example, maybe the cues for people to eat junk/high-calorie foods are so strongly triggered by other behavioral patterns that making substitutions of sugars in processed foods won\u2019t matter anyway.", "answer": 0}, {"article": "During microwave ablation, radiologists place a thin microwave antenna directly into the tumor. An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise. But more patients have to be followed for far longer to see if they stay in remission, they say.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients. Eight months later, none of the tumors had come back.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent source: American Society of Clinical Oncology spokesman Gregory Masters, MD, a medical oncologist at the Helen F. Graham Cancer Center. More sources could have deepened our understanding of the technique.", "answer": 1}, {"article": "Most cells use the energy of glucose (sugar). Some prostate cancers evolve to use energy from lipids (fat). Previous work shows that metabolizing lipids helps prostate cancer escape anti-androgen therapy. However, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source. In this study the researchers focused on the CPT1A enzyme. CPT1A helps facilitate the entry of long chain fatty acids into the cell\u2019s mitochondria for oxidation. This oxidation is vital to lipid metabolism and has been shown to aid cancer cell survival, resistance to radiation, oxidative stress, and activation of oncogenic signaling pathways.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer. \u201cSince the drugs are clinically safe, a clinical trial can be designed in patients for whom enzalutamide is prescribed.\u201d\n\u201cThis is a huge development for men with CRPC that previously did not have many options,\u201d says Isabel Schlaepfer, PhD, CU Cancer Center member, assistant professor in the Division of Medical Oncology and senior author of the study. \u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders aren\u2019t named in the news release. There is no information suggesting\u00a0that the researchers are connected to the companies that make the drugs in question or are otherwise invested in this particular treatment paradigm, but it would have been nice to be informed if this was or was not the case.", "answer": 0}, {"article": "But others would prefer to know. \u201cThis makes me feel in control of this disease,\u201d said Carol Tawney of Shawnee, Kan., a seven-year survivor who has her CA125 tested every two months.\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently. But she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\nDr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several experts who are not involved in the story, providing valuable perspective on the results.", "answer": 1}, {"article": "If there\u2019s an upside to be found in how ineffective antidepressants likely are for kids, it\u2019s that pharmacological solutions are not the recommended first line of defense, anyway. Guidelines from the psychiatric associations in most countries recommend that doctors first try psychotherapy, or \u201ctalk therapy,\u201d which is has been shown to work, at least by participants\u2019 own assessment of their depression levels (it\u2019s very hard to test therapy against a placebo, for obvious reasons). Methods such as cognitive behavioral therapy, in which psychiatrists help patients overcome destructive behaviors and thought patterns, and interpersonal therapy, which focuses more on the effect depression has on relationships, seem to be equally effective in treating depression, particularly in adolescents. Of course, this is a high-cost intervention in terms of both dollars and time invested, and it may not always be readily available\u2014but the upside is that there is no reason to believe it is harmful.\nA comment attached to the Oxford paper, written by Dr. Jon Jureidini, a child psychiatrist at the Women\u2019s and Children\u2019s Hospital in Adelaide, Australia, goes even further in decrying the use of antidepressants in kids. \u201cOnly if the discounted benefit outweighs the boosted harm should the treatment be prescribed,\u201d he writes. \u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\nThe Oxford paper notes that 3 percent of children ages 6-12 and nearly 6 percent of teenagers ages 13-18 suffered from major depressive disorder, the psychiatric term for what is colloquially known as depression. Given the U.S. population, that works out to more than a million children and adolescents. The disease manifests differently in kids: Whereas adults might report feeling apathetic, unmotivated, unfocused, and just plain sad, children with this disorder tend to be irritable and aggressive and as a result have trouble navigating social situations with adults and peers. That means that one of the first battles in treating depression in kids is recognizing it in the first place. Of course, having an effective intervention once it is recognized would help.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not mention that the study was funded by the Chinese government through the National Basic Research Program of China or that the researchers collectively have financial ties to numerous drug companies.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter sought out opinions from two clinicians not connected to the study, a patient, the Mayo Clinic, and the National Osteoporosis Foundation. But the story was not transparent about the relationships that these sources have with commercial interests. Dr. Amy Singer has disclosed significant financial ties to Amgen, which makes an osteoporosis drug. We\u2019d also note that the National Osteoporosis Foundation receives funding from a \u201cCorporate Advisory Roundtable\u201d that includes makers of bone scanning machines and osteoporosis drugs. And the Foundation has previously been called out for its failure to educate consumers about the harms of bisphosphonate drugs when those problems were first coming to light. This context should make us wary of a push to screen more men for osteoporosis without evidence that it is beneficial. Is this drive totally about the patient or could there be a commercial motivation?", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually. Deaths from prostate cancer have declined by about 40% since the advent of PSA screening in the late 1980s, and 40-70% of that decline may be attributable to screening. However, radiation therapy and surgery have a negative impact on quality of life. The uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,. Similarly, new diagnoses had fallen by 23.0-29.3% among men over age 70 and by 26.0% among infirm men, populations at risk for harms of treatment but unlikely to live long enough to benefit from early detection.\n\"Our study was designed to assess the impact of the USPSTF recommendation on screening practices among urologists and primary care providers and the incidence of prostate cancer,\" explained lead investigator Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. \"We know there is decreased utilization of PSA testing in some institutions and health systems, but has the number of incident cases per month changed substantially since the draft guideline was issued?\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not discuss funding for the study and does not disclose the fact that some authors have financial relationships with companies that make prostate cancer tests and treatments.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening. Though aneurysms can happen anywhere in the body, they most commonly happen in the brain, or in the main vessels that lead to the heart, legs and arms.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai. \u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City. \u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me. After my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study are not named (nor is the study that led to the device approval identified or linked). It is good to know that the surgeon featured in the news release, Dr. Azizzadeh, works \u201cin conjunction with medical device company Medtronic, [and] served as the national principal investigator in clinical tests of the device.\u201d", "answer": 0}, {"article": "Kerry Aldrich, 15, suffered a concussion playing varsity soccer for The Potomac School in McLean, Va., three weeks ago when she did a face-first dive and violent somersault.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\nOne expert says doctors have learned more about concussions in the past five years than in the previous 50.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe broadcast includes interviews with an independent expert who describes the potential problems posed by premature return to play. However, it fails to mention that the other expert interviewed, Michael Collins, PhD, is a part owner in the company that developed and licenses the Impact system.\n", "answer": 0}, {"article": "NIAID conducts and supports research \u2014 at NIH, throughout the United States, and worldwide \u2014 to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital. Dr. Nash served as principal investigator of the HALT-MS study.\nIn HALT-MS, researchers tested the safety, efficacy and durability of HDIT/HCT in 24 volunteers aged 26 to 52 years with relapsing-remitting MS who, despite taking clinically available medications, experienced active inflammation, evidenced by frequent severe relapses, and worsened neurological disability.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was sponsored by the National Institute of Allergy and Infections Diseases and the NIH. But it does not mention that Baxter Healthcare Corp. supplied equipment for the trial or that several study authors have financial relationships with biotechnology companies, which are listed in the study.\nIt\u2019s not easy to determine which companies have financial interests in hematopoietic stem cell transplantation, but Baxter has at least one patent relating to the procedure. This makes full disclosure an important aspect of the reporting of this trial. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A few different independent experts raise concerns about the quality of the evidence supporting these products, their effectiveness, and their potential to cause harm. And the story seems to identify relevant commercial relationships that represent a conflict of interest. This was the major strength of the story; but\u00a0as noted above, we think these sources could have been put to better use.", "answer": 1}, {"article": "Embryonic cells can also form tumors if injected into the body. Dr. Robert Lanza, chief scientist at Advanced Cell, said the company had to prove to the F.D.A. that its retinal cells contained virtually no residual embryonic stem cells. It took a year for the company to get clearance for the trial from the F.D.A.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible. Also, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert source quoted in the story was an investigator on the study of the new drug. Although the story disclosed that he was a consultant for the drug\u2019s manufacturer, Regeneron,\u00a0it should have sought out a comment on the findings from\u00a0somebody with no stake in the research. This is especially important considering the findings were not published in a journal and presumably have not been vetted by other researchers.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one truly independent of the Medtronic-Lilly partnership was quoted.\u00a0 We would have liked to have seen independent expert perspective on the approach.", "answer": 0}, {"article": "DHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\n\u201cWe must bear in mind that this is a pilot study with a small sample,\u201d Anna Fenton, co-editor of Climacteric, said in commentary on the work. \u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\nFor this trial, a team of researchers led by Andrea Genazzani of the University of Pisa followed a group of 48 post-menopausal women with troubling symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not quote any outside sources, which we know can be driven by deadline demands. The bigger problem with the story, and it\u2019s a problem shared by many stories about hormone treatments, is that it does not acknowledge the authors\u2019 conflicts of interest. Dr. Andrea Genazzini, for example, has worked with pharmaceutical companies on multiple articles that were ghostwritten by the companies\u2019 marketing firms. You can find this by looking in the Drug Industry Document Archive. We know that it\u2019s tough to cover all the bases when juggling multiple stories in a day, but we hope that more reporters will take the time to at least do a name check on researchers involved in studies of hormone therapy, antidepressants and other drugs that have been the subject of lawsuits and federal investigations. There is a wealth of information in the archive, and readers deserve to know more about it.\n\u00a0", "answer": 0}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote an independent source in the story, rather than relying on the study\u2019s authors.\u00a0 It does not, however, provide any information relating to possible conflicts of interest. For example, the study was funded by a large ophthalmology clinic where this procedure is presumably performed \u2014 and which might stand to gain more business if it\u2019s proven to work effectively.", "answer": 0}, {"article": "Enhanced awareness through breathing techniques and specific postures. Schools vary widely, aiming to achieve total absorption in the present and a release from ordinary thoughts. Studies are mixed, but evidence shows it can reduce stress.\nThe mindfulness treatment \u201cmay be contraindicated for this group of patients,\u201d S. Helen Ma and Dr. Teasdale of the Medical Research Council concluded in a 2004 study of the therapy.\nDr. Kabat-Zinn taught the practice to people suffering from chronic pain at the University of Massachusetts medical school. In the 1980s he published a series of studies demonstrating that two-hour courses, given once a week for eight weeks, reduced chronic pain more effectively than treatment as usual.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job balancing comments from several leading proponents of mindfulness therapies with summaries of the evidence of this practice in clinical trials. The story discusses caveats that the practice may be useful as part of an integrative treatment plan; however, evidence suggests it is not a panacea for depression or anxiety, and it should be used with caution (or not at all) with some patients.\u00a0 The journalist should be commended for the range of mindfulness experts, clinicians and patients interviewed in the article. This is a well-balanced report providing the reader with good information on a trend in medicine, but appropriately tempering over-enthusiam for the practice with available evidence.\u00a0 ", "answer": 1}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin. They were dosed before bed time and had their overnight glucose levels continuously monitored. Those who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\n\u201cIt\u2019s been a long trip but it\u2019s finally at the point that it\u2019s beyond a doubt, the oral insulin works,\u201d Nadav Kidron, chief executive of Jerusalem-based Oramed, said in a telephone interview.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from the CEO.\u00a0Getting an independent voice is especially important when the data is preliminary and comes from the pharmaceutical company.", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels. We cultivate evidence-based knowledge, provide extensive educational programming, and promote emerging research that advances the science and practice of sports medicine. AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders. However, seeing this type of success allows sports medicine physicians another option in older patients and serves as a predictable biologic joint preservation technique,\" said Crawford.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not say how the research was funded, nor does it address conflicts of interest. To be clear, the research may have been internally funded, and there may well be no conflicts of interest \u2014 but it\u2019s important for a release to state that explicitly.", "answer": 0}, {"article": "WATCH: The naked mole rat might help us cure cancer\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis. \n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites independent commentary from an accompanying editorial that provides useful context. Inclusion of a second independent voice might have drawn attention to some of the study\u2019s limitations as discussed above. The story doesn\u2019t discuss potential conflicts of interest among the study authors, but the only conflict disclosed with the manuscript was related to a company that makes thermometers. Overall, this seems Satisfactory to us.", "answer": 1}, {"article": "Mothers reported their use of prenatal vitamins or other supplements before, during, and after pregnancy.\nThe research needs to be duplicated, Hertz-Picciotto tells WebMD. Still, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\n\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who was not involved with the research and who is identified as working for an advocacy group. There don\u2019t seem to be any other potential conflicts to disclose.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts who have differing views on the value of the new information. It did an especially good job of noting conflicts of interest where they existed. ", "answer": 1}, {"article": "Doctors can estimate a woman's chances of developing breast cancer based on a variety of factors, including her age and family history, but most women have no way of knowing their precise risk. Women with a strong family history can get tested for two genes that sharply increase their predisposition, but they account for only 1 to 3 percent of all breast cancers.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology. \"I fear for many women the results could be quite misleading.\"\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others. Some questioned its reliability, while others worried that the results could either lull women into a false sense of complacency or needlessly alarm them, prompting them to take unnecessary tests or even undergo unneeded surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test\u2013unlike Decode\u2019s chief executive, who is also interviewed, mainly promoting his company\u2019s product.\u00a0 Researchers help educate the reader about a new test may have many more cons than pros.\u00a0 The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts.", "answer": 1}, {"article": "People who'd boosted their physical activity level after being diagnosed with lymphoma also were less likely to have died in that three-year span than were those who hadn't increased their activity level.\n\"Importantly, our study shows a survival benefit in patients who increase their level of physical activity,\" Pophali said. \"Therefore, since physical activity behaviors can be modified, physicians should counsel patients and survivors on the importance of physical activity and encourage them to maintain and, if possible, increase their level of physical activity.\"\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story, nor does the story tell readers who funded the relevant study or whether there are any potential conflicts of interest among the researchers. (The study abstract itself doesn\u2019t tell readers who funded the study, though it does list the various industry relationships of the researchers.)", "answer": 0}, {"article": "Cataracts are the leading cause of blindness in the world, and are often related to aging. In a common form of cataracts, proteins in the lens change over time, developing chromophores \u2014 molecular add-ons that absorb color in the blue part of the spectrum. Chromophores reduce the amount of light reaching the retina (and give the lens a yellow-brown appearance), but they also disrupt the structure of the lens proteins, causing light to scatter.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure. Much more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery. In their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. ", "answer": 0}, {"article": "Pancreatic cancer has one of the lowest survival rates of any cancer, with only 4 percent of patients surviving five years after diagnosis. That is due in part to the lack of any easy way to detect the cancer in its earliest stages. The pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams. Patients usually have no symptoms until the cancer has spread.\n\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D. Anderson and a co-author of the study. \"This presents an unprecedented opportunity for informative early detection of pancreatic cancer and in designing potential curative surgical options.\"\nScientists have uncovered various markers that can be used to detect the cancer through a blood test, but those have been too unreliable to recommend widespread screening.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert quoted in the story is a coauthor of the study. We think it\u2019s always prudent to consult an independent third party to vet claims. In addition, while the story includes some background on the prevalence and outcomes of pancreatic cancer, these reviewers were disappointed to see that these statistics were not sourced. There are a couple reasons why attributing sources of claims and statistics is important. Obviously, readers may want to do additional reading and providing a source points them in the right direction. Another reason it\u2019s important to provide attribution is that statistics have been known to vary among advocacy groups, medical associations, companies, foundations and government institutions. It\u2019s not unheard of for groups pushing for more awareness and funding to select a higher number \u2013 among those available \u2013 to further their cause.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did mention where the research was conducted and the journal in which it was published.\u00a0 However, it did not contain any obvious input from experts in the field.", "answer": 0}, {"article": "He also keeps his blood pressure down by exercising and paying attention to his weight and diet. \"I'm a believer,\" he says.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an official of the Alzheimer\u2019s Association, which has an obvious interest in the prevention and treatment of AD. But NPR would have added much credibility to the story with some cautionary note from outside sources about the nature of the evidence for blood pressure control and AD prevention.", "answer": 0}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor. Electrical pulses scramble or block the pain signals traveling through the nervous system, preventing them from reaching the brain.\nEvery patient received conventional pain treatment, but half were also given a spinal cord implant. Pain fell by half for 48 percent of the implant patients but only 9 percent of the others.\nThe implants cost about $20,000, and the procedure, hospital care and follow-up can bring the total bill to about $40,000. In August, the medical journal Neurosurgery showed that spinal cord implants were far cheaper than additional operations to treat pain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides a good mix of sources, including one patient and three pain experts (one of whom relates the story of a dissatisfied patient). It also reports a potential conflict of interest among the authors of the study it cites, as well as with one of the expert sources.", "answer": 1}, {"article": "But Himpens tells WebMD he's skeptical either would make much difference. \"My impression is, even with the newer band, the results are not significantly better,\" he says.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found. The average weight loss was below what experts consider good results. Even so, a majority of the patients in their small study said they were satisfied with the procedure.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview comments from a company spokesperson and one of the authors of the study, both of whom were clearly identified. \u00a0The story also included this important detail about the quoted author, which was missed by the HealthDay story we reviewed. \u201cHimpens reports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.\u201d In addition, the story had comments from two surgeons who do not appear to have direct ties with either the manufacturer of the product or the study reported on. We were a little concerned about some of the phrasing in the story. It says, \u201cBut some, including the manufacturer of the Lap-Band \u2014 used in a technique called laparoscopic adjustable gastric banding \u2014 take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.The critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\u201d This leads readers to believe that there are mulitple critics out there pointing out flaws in the study. The story itself, though, only quotes one actual critic: the company spokewoman. The criticisms may be valid, but readers deserved a strong independent analysis of the study\u2019s limitations.", "answer": 1}, {"article": "Galveston, Texas 77555-0144 \nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nUsing the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014. They also used the national Medicare database to study data from 253 men with COPD aged 66 and older who initiated testosterone replacement therapy between 2008 and 2013.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study are not named in the release. The lead author, we learn in the full paper, \u201chas received payment, for consulting, from AbbVie, Endo Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, and Auxilium Pharmaceuticals.\u201d\u00a0Some of these companies manufacture testosterone replacement therapy.\u00a0 This was not mentioned in the news release.", "answer": 0}, {"article": "Reducing cholesterol can have a positive effect on many chronic liver disorders, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, as well as in biliary disorders. In some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels). Statin use may also lead to:\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology. NOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Since this was based on a review article we don\u2019t require a named funding source to rate this satisfactory. Nor do we have any evidence that the authors have any conflicts of interest. If there was, we would expect the news release to include them. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Multiple sources are quoted.", "answer": 1}, {"article": "The U.S. government currently recommends screening for high cholesterol in children with a family history of heart disease or high cholesterol (with at least one parent or grandparent who has suffered a premature heart event such as heart attack or stroke, or at least one parent with total cholesterol levels above 240 mg/dL). The guidelines also recommend that youngsters whose parents are not aware of their family history of heart disease be screened.\nThe current guidelines were put in place in the 1990s, and at the time, experts predicted that high cholesterol would be missed in as many as 25% of children, says Neal. But doctors assumed that in most cases, these children would have only slightly elevated cholesterol levels that would eventually be detected when they became adults and would be lowered with diet and exercise.\nSacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes. \"The weight of the child, his waist circumference and whether he has siblings who are overweight would help to select a group that is at greater risk of having high cholesterol,\" he says. \"Now that we have this data, it does call into question these original guidelines from the government.\" The next update of the recommendations is expected in spring 2011.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe journal Pediatrics stated that the study authors did not have any relevant financial interests. The story does include comments from an independent expert; however, the independent expert addresses only questions about the efficiency of screening, not the health benefits or harms of identifying children with elevated cholesterol.", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As already noted, the quote from the California geriatric neurologist was crucial.\u00a0 But other independent experts were quoted as well.\u00a0 Excellent sourcing.", "answer": 1}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives. Also, hospitals are dangerous places for very sick people; they may get fatal blood infections, pneumonia or bedsores, or simply be overwhelmed by the powerful drugs and radiation attacking their cancer.\nSaying the study was \u201cof critical importance,\u201d Dr. R. Sean Morrison, president of the American Academy of Hospice and Palliative Medicine, said it was the \u201cfirst concrete evidence of what a lot of us have seen in our practices \u2014 when you control pain and other symptoms, people not only feel better, they live longer.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strong effort here. The story quotes one of the study authors,\u00a0an independent\u00a0editorialist, a physician-writer knowledgeable\u00a0about end-of-life\u00a0care,\u00a0as well as leaders of professional groups that support hospice and palliative care.\u00a0", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes some good contextual comments from\u00a0Dr. James Aisenberg, a gastroenterologist and clinical professor of medicine at Mount Sinai Medical Center in New York. It also points out that there is a financial upside for the lead researcher in the study and the company that helped fund it: \u201cDr. Zalis and some of his co-investigators developed the software. The American Cancer Society, the National Institutes of Health and General Electric Co.\u2019s health-care unit\u2014which markets scanning devices and accessories\u2014supported the researchers. Dr. Zalis says the company had no influence on the study.\u201d", "answer": 1}, {"article": "Scientists have transformed one type of fully developed adult cell directly into another inside a living animal, a startling advance that could lead to cures for a variety of illnesses and sidestep the political and ethical quagmires\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did include interview material from individuals not directly connected with the study reported on. And the story did include a comment from a stem cell researcher indicating that it is likely not a quick, straight shot from these results to use in people. The other sources interviewed provided a modicum of balance. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer notes her prior position as director of NIH, and cites the chief of the Women's Health Initiative branch of NIH. ", "answer": 1}, {"article": "Learn more about colon cancer from the U.S. National Cancer Institute.\nAltomare's team acknowledges that there is a lot of work left to do. It's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nThe study, of 78 people with and without colon cancer, found that those with the disease tended to have a distinct pattern of chemicals in their breath. And when researchers analyzed the study participants' breath samples, they correctly identified the colon cancer patients 76 percent of the time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An expert from the American Cancer Society\u00a0provides much-needed context and perspective on this research.", "answer": 1}, {"article": "The controversy over when a woman should get mammograms is about to heat up again.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades. Women should trust that process, she said.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations. This results in confusion and puts more than 22 million women at risk of losing of losing insurance coverage for mammograms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from several independent sources. Comments from Fran Visco of the National Breast Cancer Coalition are worth repeating: \u201cWomen are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions.\u201d", "answer": 1}, {"article": "Nearly half of women taking flibanserin (and nearly a third of women taking placebo) reported at least minimal improvement in \"bothersome decreased sexual desire.\"\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nUpdated reports on data from the North American \"Daisy\" and \"Violet\" studies were made by Krychman and other researchers at this week's annual meeting of the American College of Obstetricians and Gynecologists in San Francisco.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest are disclosed.\u00a0 The story noted that the study researcher\u00a0interviewed is a paid consultant for the drug manufacturer.\u00a0 An alternative point of view is provided by\u00a0two independent experts, a\u00a0psychologist and a sex-therapist.\u00a0 The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers.\u00a0 ", "answer": 1}, {"article": "Click for more from The Sun.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes that were collected by the Science Media Centre, yet this wasn\u2019t disclosed. The other quote was from the news release, which also wasn\u2019t attributed.", "answer": 0}, {"article": "Folic acid is found in leafy green vegetables, fruits, dried beans, peas and nuts. In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\n\"We know that folate plays a really critical role in brain development and brain function,\" said Dr. Daniel Armstrong, associate chair of pediatrics at the University of Miami Miller School of Medicine.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted. In fact, folate deficiencies may be involved in the development of autism, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from a clinician without apparent ties to the story were included in this story.", "answer": 1}, {"article": "Diabetes is a growing problem. O'Neil said the rate jumped from about 9 percent to 12 percent between 2002 and 2012. Weight loss is seen as a good way to slow its progression.\nThe multi-site study's results were statistically and clinically significant, O'Neil said.\n\"The Weight Watchers people were significantly better off than people who received standard care.\" They achieved better control of their blood sugar and lost more weight, he said. They still had diabetes, but many were able to reduce the amount of medication they were taking.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes clear that Weight Watchers funded the study but does not disclose the lead investigators other financial ties to Weight Watchers. The published study states that several of the authors were Weight Watchers employees, held stock in the company, served on its board or were Weight Watchers product patent holders.", "answer": 0}, {"article": "To Drill Or Not To Drill\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\n\"We aim to treat these intermediate lesions -- not the very early ones, but the intermediate ones -- where usually, as a dentist, you are not sure whether you should make a filling or not,\" Paris says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nAlthough this story includes comments from an independent source and it identifies the lead researcher as being on of the product\u2019s developers\u2026 it fails to point out that the dentist featured in the story also has received financial support from product\u2019s manufacturer.\nReference: http://www.compendiumlive.com/print.php?id=3103", "answer": 0}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe results allow researchers to compare the predictive ability of a large number of health-related risk factors which were formerly studied separately and using different populations, although the predictive ability of risk factors does not necessarily imply they are causally related to the risk of dying.\n\"The Ubble website allows anybody in the UK between forty and seventy years old to calculate their 'Ubble age' and their risk of dying within the next five years compared to the general population, using a simple set of a dozen or so questions,\" says study co-author Professor Erik Ingelsson from Uppsala University, Sweden. \"This is the first study of its kind which is based on a very large study sample, and is not limited to specific populations, single types of risk, or requiring laboratory testing.\" [4]\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are clearly identified in the notes at the bottom of the press release.\u00a0 The investigators assert the absence of conflicts of interest in the journal article itself.", "answer": 1}, {"article": "Shares of Zafgen, which traded as high as $55.36 on the Nasdaq stock exchange last year, closed Tuesday at $5.62, down nearly 3.3 percent for the day.\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nWhile the FDA\u2019s clinical hold prevented Zafgen from completing its trial, Dennis D. Kim, the company\u2019s chief medical officer, said it was largely finished. Sixty-eight of the enrolled patients completed the study, Kim said, while 27 other patients completed 20 of the trial\u2019s scheduled 26 weeks. A small number of other patients withdrew early.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two sources appeared to have been interviewed for this piece, Dr. Hughes and Dr. Butler. The former is the chief executive of Zafgen while the latter is a medical researcher serving as a principal investigator of the clinical trial at the University of Kansas Medical Center. To meet our standard here, the story would have had to interview a source completely independent of the company and the trial. We rate this Not Satisfactory, but at least the article makes it clear that the studies under consideration are for a commercial drug.", "answer": 0}, {"article": "By contrast, surgical cancer removal often means several hours in the operating room, complications of general anesthesia and weeks or months of recovery. Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nPhysicians participating in the trial report that patients feel minimal discomfort and can watch the procedure on the ultrasound screen. Most are extremely relieved to avoid painful, disfiguring surgery and long recovery times.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial. \"For older patients the risks associated with invasive procedures and general anesthesia as well as the discomfort of long recoveries also makes this procedure particularly desirable. As our understanding of tumor biology grows, the ability to offer treatment options other than surgery is important.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "IceCure Medical, the manufacturer of ICE3, is named as the source of the\u00a0release.", "answer": 1}, {"article": "NEW YORK April 25, 2018 - A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri. \"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not give us information on funding or conflicts of interest. The full journal article states there are no conflicts.", "answer": 0}, {"article": "In fact, as a Federal Register posting last year chronicled, there have been questions raised about whether 17-HP caused birth defects of various kinds. In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects. They later revoked them.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES. In 1971 researchers realized children exposed to DES in utero had a higher incidence of vaginal and breast cancers, and males were subsequently found to have urinary-tract problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The medical director of The March of Dimes was quoted throughout. (Although they are seen as having a very pro-progesterone slant that is not held by consumer/advocacy/health policy/maternity care groups in UK, Australia, and Canada. in those countries surveys of providers uniformly get low utilization responses with the reason stated being need for more data. Similar surveys of US providers (specialty and generalists) show the vast majority use >70% (as opposed to low double digits in more evidence-driven countries) and that mission creep has started. Indications for which it is not tested see regular use in the US.)", "answer": 1}, {"article": "The compressions also have to come in rapid succession - about 100 per minute. According to Hazinski, one easy way to remember the rhythm is that it is roughly equivalent to the beat of the 1977 Bee Gees' disco hit \"Stayin' Alive.\"\n\"Many times people nearby don't help because they're afraid that they will hurt the victim and aren't real confident in what they're doing,\" said Michael Sayre, chairman of the Heart Association committee that rewrote the guidelines.\nAlthough survival rates for cardiac arrest hover around 10 percent with CPR, Hazinski noted that rates have been pushed as high as 30 percent in cities, such as Seattle, that combine high bystander participation with a strong system of professional emergency medical response.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites three sources, two of them associated with the American Heart Association (which developed the new guidelines) and one an apparently independent expert who supports the guidelines. ", "answer": 1}, {"article": "The American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools. The association is directed by volunteer leadership and fosters ongoing, direct member-involvement through its 51 chapters. AMTA works to advance the profession through ethics and standards, the promotion of fair and consistent licensing of massage therapists in all states, and public education on the benefits of massage.\nIn a controlled study composed of HIV-positive adolescents, participants who received massage therapy showed enhanced immune function by the end of the 12-week study. The immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA). \"Those same benefits translate to people seeking to fight off the common cold, flu and other seasonal illnesses.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t list who the funders were for each study and whether there were any conflicts of interest.\nThe release is clearly identified as coming from a professional association and it\u2019s evident its purpose is to drive new customers toward association members.", "answer": 0}, {"article": "OraVerse does the opposite, dilating the blood vessels and speeding up blood flow so the anesthetic can be carried away.\nNovalar also said patients did not have pain because the anesthesia wore off more quickly, except for a little extra pain at the injection site. But the trials excluded people who got root canals or tooth extractions. Those patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed only company executives and dentists who consult with the company. No independent medical sources were consulted.\u00a0 \nGiven the questionable premise of the product, this is a remarkable omission. ", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has only one expert quoted, and that expert is an author of the study. Someone independent of the study would be in a better position to evaluate the claims objectively.", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables. \u201cYou can eat massive amounts of plant material and it can be incredibly good for you, you can feel really satisfied and full,\u201d Sonnenburg says. \u201cI find that a really nice way to eat\u2014just kind of gorging myself on plant material.\u201d\n\u201cYou really hold the reins to guiding this community [of bacteria] through the choices you make,\u201d says Justin L. Sonnenburg, PhD, associate professor in the department of microbiology and immunology at Stanford University School of Medicine and author of . Sonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut. Studies done on single fibers\u2014those, like inulin, which are added to foods\u2014haven\u2019t shown to have the same effects as fiber that occur naturally in whole foods. \u201cAll of the vegetables we\u2019re encouraged to eat by our mothers and by the government guidelines, these are all filled with fiber, and filled with a diversity of fiber, and probably the best route for encouraging a diverse microbiota,\u201d Sonnenburg says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes one source who was not affiliated with the relevant study, but makes clear that the source is a vocal proponent of the idea that a high-fiber diet is important for maintaining a \u201chealthy\u201d gut microbiome and that the microbiome can have a significant impact on health.", "answer": 1}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included no quotes from the researchers or outside sources\u2013both could have provided important context and caveats about this kind of early-stage animal research, and the emerging results of this chemical, which also made recent headlines in cancer research, making us curious about why this study, now.\nAs for conflicts of interest, the article didn\u2019t mention any, and because the study coauthors declare none, we will assume that to be the case.", "answer": 0}, {"article": "(Philadelphia) - High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other. For the first time, researchers have shown that more patients live longer if treated with the combination of prostate removal plus radiation therapy. The research was published September 25th in the journal Cancer.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study. \"We recognized that it may have curative potential.\"\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer. \"Two modes of treatment are recommended by both United States and European guidelines for cancer treatment. It was surprising to see only 29 percent of patients received the recommended combination therapies, and as many as 20 percent are not getting any treatment six months after their diagnosis,\" said Dr. Lu-Yao. \"Our data can't tell us the reason for this deviation from guidelines and further studies are needed.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release stated that the study was funded by the New Jersey Health Foundation, the National Cancer Institute, and the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nNewby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is an independent source quoted. However, the story does not mention that the senior researcher quoted throughout the story had disclosed \u201chonoraria and consultancy from Toshiba Medical Systems,\u201d a manufacturer of CT scanners. There is also no mention of the funding of the study, though the funding description in the journal article says it came from a mix of public agencies and foundations, not from an industry source.", "answer": 0}, {"article": "Much about DHA is unknown. Its effect in supplements for children and adults is being studied, as well as whether supplements offer the same benefit as DHA-rich fish, like salmon.\nNonetheless, several experts said they would continue to support taking DHA in pregnancy, especially since it is safe and apparently has few downsides. They cited a smaller 2003 Norwegian study that found I.Q. increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nDr. Makrides\u2019s team plans assessments at 4 and 7. Dr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several independent sources quoted/cited in the story. ", "answer": 1}, {"article": "The study was funded by the P.J. Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy. \"But if patients have a high calcium score and are in the gray zone, then it would make sense to go with 120 as a treatment goal.\"\nThe scans detect levels of calcium in the heart's arteries, and the physicians suggest those people with the highest calcium levels would benefit most from aggressive blood pressure treatment, whereas those with little or no calcium may not need to be treated as intensively, depending on their other heart disease risk factors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions who funded the study, but it omits one potential conflict of interest that was reported in the study: one of the authors serves on a speakers\u2019 bureau for GE Healthcare, which makes imaging equipment and software designed to detect coronary artery calcification. It\u2019s not a a major concern, but the lack of disclosure means the release doesn\u2019t quite meet our standard here.", "answer": 0}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree. The seeds are dried and then processed to produce cocoa powder. Dark chocolate generally has a higher percentage of cocoa content than milk chocolate.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email. \"When looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\"\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story discloses that the research was conducted by Hershey scientists, and it solicits comments on the findings from an expert who was not affiliated with the study. Although this is\u00a0enough for a satisfactory, we wish the story would have\u00a0sought out someone with a more skeptical take\u00a0on the results.\u00a0This\u00a0expert\u2019s comments \u2014\u00a0\u00a0\u201cWhen looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\u201d\u00a0\u2014 don\u2019t do much to help readers put the findings in the appropriate context.", "answer": 1}, {"article": "About Freespira\nEarly data from a fifth study reported on Freespira treatment for patients with Post-Traumatic Stress Disorder (PTSD). Ninety percent of patients in this study experienced a significant improvement in PTSD symptoms at two months and six months post-treatment.\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are not told the source of money for any specific clinical trials. The release was written by Palo Alto Health Sciences, the company that sells the Freespira system. But we aren\u2019t told if the company\u00a0 supported any of the clinical trials financially and without access to the studies, we can\u2019t look up any potential conflicts of interest disclosures.", "answer": 0}, {"article": "Though African studies have linked circumcision in adult men to lower rates of sexually transmitted diseases, including the virus that causes AIDS, Perera said that only future studies will tell if those findings are applicable to the Western world, where AIDS is much less prevalent.\nDr. Matthew Golden, an associate professor of medicine at the University of Washington Center for AIDS and STD, said the ideal study would randomly assign thousands of infants to either get circumcised or not get circumcised and then follow them for decades. But \"that trial is never getting done, nor should it be done,\" Golden said.\nAs to whether circumcision reduces sexual sensitivity, Perera said there's no evidence that it affects sensation when performed on adults. The highest-quality studies, known as randomized controlled trials, don't report whether infant circumcision affects sensation, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "The MU School of Medicine has improved health, education and research in Missouri and beyond for more than 165 years. MU physicians treat patients from every county in the state, and more Missouri physicians received their medical degrees from MU than from any other university. For more information, visit http://medicine. .\nVogel's research team reviewed nearly 20,000 cases where patients either had open surgery or an endovascular repair - a minimally invasive procedure that uses a catheter to access the aneurysm. The team then identified patients who took cholesterol-lowering medication before surgery.\n\"This information could be beneficial to patients who are about to have elective endovascular abdominal aortic aneurysm repair,\" Vogel said. \"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It appears this epidemiological study received no outside funding so we believe it\u2019s safe to conclude there is no conflict of interest.", "answer": 1}, {"article": "Many heart doctor will tell you that one of the best ways to keep your heart healthy is to include more healthy oils, such as omega-3 fatty acids found in fish, in your diet. Studies have shown that people in parts of the world who eat more fish have lower rates of heart disease, and fewer heart attacks (though the same can\u2019t necessarily be true of those who take supplements\u2014see this piece \u201cFish Oil Is Hugely Popular\u2014But Should You Take It? for more on that).\nBased on analysis of their blood samples, the people taking omega-3 supplements also showed lower levels of inflammatory markers, which suggests that the fish oil may be working by reducing inflammation following a heart attack.\nFor the study, published in the journal , they studied nearly 360 people who recently had a heart attack, who were randomly assigned to take 4g of omega-3 fatty acids or a placebo pill for six months. (That\u2019s a high dose; a 3 oz. portion of salmon contains anywhere from half a gram to 1g of omega-3.) Every two months, the volunteers came in for an MRI of their heart to track how much the muscle was changing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the lead investigator, Dr. Raymond Kwong, was interviewed.", "answer": 0}, {"article": "Eating tomatoes in your daily salad or regularly enjoying a healthy red sauce on your spaghetti could help reduce your risk of stroke, according to research published this week in the journal Neurology.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure. Elevated blood pressure is major risk factor for stroke.\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York. \"But it's not proof that if you eat tomatoes you're going to have less risk of stroke.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was\u00a0excellent input from independent experts on stroke and nutrition. This was a strength of the story.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Despite recent debate about how well antidepressants really work in people with only mild or moderate depression, a new analysis of drug studies suggests they may have some benefit across the board.\n\u201cThe idea that unless you\u2019re very, very ill, you\u2019re not going to benefit from treatment does not appear to stand up\u201d when looking closely, said the study\u2019s lead author, Robert Gibbons, from the University of Chicago.\nFor their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills. Most of those trials were funded and run by the pharmaceutical companies that manufacture Prozac and Effexor \u2014 Eli Lilly and Wyeth, respectively.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story interviewed Irving Kirsch, frequently cited/quoted on antidepressant research issues.\nIt also did a good job of noting potential conflicts of interest.", "answer": 1}, {"article": "PHILADELPHIA -- Labor is an intensely strenuous activity, with the uterine muscle contracting every few minutes to reposition a baby through the pelvis and down the birth canal. Even low levels of dehydration can seriously compromise normal physiological function, yet recent studies looking at hydration in laboring women via the rates of intravenous (IV) fluid showed conflicting results. By pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase. The results were published online as an accepted article in Acta Obstetricia et Gynecologica Scandinavica.\n\"We've known that it's important for women to stay well hydrated during pregnancy and labor. This study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella. \"Recently, we also showed that letting women eat more liberally in labor, especially in early labor, has benefits including shorter labor, and no identifiable risks.\"\nDr. Berghella and colleagues compiled data from seven small clinical trials that collectively included a total of 1,215 women. Of those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour. General practice in the United States is to administer IV fluids at 125 milliliters per hour during labor.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note funding sources but the research report indicates that the scientists received no financial support, a situation not uncommon when analyzing existing data. The release does explicitly state that none of the investigators has a conflict of interest.", "answer": 1}, {"article": "Falling whilst skiing, tumbling down the stairs or getting hit on the head can cause symptoms such as blurred vision, vomiting, loss of consciousness or memory for about 30 minutes. There is then a risk of mild cerebral trauma, which represents more than 90% of brain injuries admitted to hospitals. But is there really a brain lesion? Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma. As their case is not a priority, it often takes a long time for the majority of patients to return home without risk of sequelae, except for bad memories.\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study. \"Today, our research shows that the results are even more accurate when we combine H-FABP and GFAP levels,\" continues Jean-Charles Sanchez. \"We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.\" ABCDx's ultimate goal is to bring to market biomarkers capable of diagnosing brain trauma, stroke and aneurysms. \"Biomarkers are a mine of information on patients' state of health, it is up to us to decode them,\" concludes the Geneva researcher.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release stated that the test sponsor, the University of Geneva, holds a patent on the test which was developed by two of the study\u2019s authors who founded the company that will sell the test.", "answer": 1}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that one source, Aaron J. Kowalski, PhD, is affiliated with the Juvenile Diabetes Research Foundation (JDRF), and says that he \"did not take part in the study.\" However, it does not disclose\u00a0that JDRF was a sponsor of the study, which\u00a0means that\u00a0Dr. Kowalski could be more likely than a truly independent observer to look favorably on the results.\u00a0\nThe story also did not identify\u00a0the financial\u00a0ties between one of the investigators quoted in the study and a study sponsor.", "answer": 0}, {"article": "\"We can now pinpoint prostate cancers using MRI scans and targeted biopsies, allowing a much more targeted approach to diagnosis and treatment. This means we could accurately identify men who would benefit from VTP and deliver treatment more precisely to the tumour. With such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission. We also hope that VTP will be effective against other types of cancer - the treatment was developed for prostate cancer because of the urgent need for new therapies, but it should be translatable to other solid cancers including breast and liver cancer.\"\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. \"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up. We would also expect the treatment to be far more precise if we repeated it today, as technology has come a long way since the study began in 2011.\nThe trial involved 47 treatment sites from ten different European countries, most of which were performing VTP for the first time.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the trial was funded by Steba Biotech, which holds the commercial license for the treatment. However, it does not mention that all of the study authors received compensation from Steba, and some also receive money from other biotech firms.", "answer": 0}, {"article": "The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute\u2019s Department of Science Education. The AP is solely responsible for all content\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used a range of sources. It noted that one source, Yale University psychiatrist Gerard Sanacora, PHD, MD, has worked for companies seeking to develop ketamine-based drugs.\nOne quibble: The story devoted substantial ink to positive anecdotes. Was the reporter able to find patients with negative experiences involving ketamine? That would be interesting to know.", "answer": 1}, {"article": "Supplements may be an additional source of DHA, but an editorial in the same issue, by Dr. Martha Clare Morris, an associate professor of medicine at Rush University Medical Center in Chicago, points out that there are no published human studies of the effects of omega-3 fatty acid supplementation. The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe. High intakes of fish oil can cause excessive bleeding in some people.\n\u201cThis study doesn\u2019t prove that eating fish oil prevents dementia,\u201d he said. \u201cIt\u2019s an observational study that presents an identified risk factor, and the next step is a randomized placebo-controlled study in people who do not yet have dementia.\u201d Dr. Schaefer is chief of the Lipid Metabolism Laboratory at Tufts University.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story was based on information from an original research study and included quotes from the study senior author as well as material from an editorial about the research study.", "answer": 1}, {"article": "Texting also played a role in helping patients feel like they were in control of their treatment, particularly during the first month.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase. At the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources. While we couldn\u2019t identify any conflicts of interest, some of the researchers receive payments from industry. The article fell short by not indicating who funded the study.", "answer": 0}, {"article": "Several explanations exist for why a strict diet, low in calories but high in nutrients, may slow aging. Many scientists think that an important factor in aging is DNA damage caused by free radicals, highly reactive oxygen-containing molecules formed during normal metabolism. Eating less leads to a slower metabolism and fewer free radicals.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction. The participants, who were paid, turned out to be highly motivated, he said. Some were concerned about their weight and health. They had to take time off work for metabolism tests and also ate many meals at the clinic.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature. Both are considered signs of longevity, partly because an earlier study by other researchers found both traits in long-lived people. The diet also led to a drop in thyroid hormones and declines in DNA damage.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main expert quotes in the story came from people with a vested interest in showing positive results. Evan Hadley of the National Institute on Aging (source of funding for the study) called the results of this pilot study \u201cstriking\u201d. In addition, an estimate for the number of individuals currently engaging in calorie restriction appears to have been obtained from the president of the Calorie Restriction Society. While this study is one of three pilots studies for the feasibility of calorie restriction in humans, no comments from the other research groups was included. ", "answer": 0}, {"article": "Patients with chest pain symptoms require multiple blood tests over several hours before a diagnosis is reached. Previous studies using high-sensitivity cardiac troponin alone to rule out and rule in heart attacks have not consistently demonstrated sufficient safety to use in clinical practice.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario. According to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack. These blood tests are part of the World Health Organization's list of essential in vitro diagnostics tests for health care facilities with clinical laboratories.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder\u2014the Canadian Institutes for Health Research\u2014is clearly identified.\u00a0 Conflicts of interest among the many coauthors, however, are not mentioned.\u00a0 The original research article offers a lengthy list of potential conflicts; for example, the two coauthors quoted in the news release have begun the process of patenting the laboratory scoring system discussed in the research.\u00a0 And the first author of the paper, one of those quoted, has received research funding and honoraria from a number of drug companies.", "answer": 0}, {"article": "As in 90 degrees below zero.\nTechnically known as single-port cryosurgery, the technique is used only for cancers no bigger than an inch and a half wide that haven't spread beyond the kidney, Lee said.\nWhile kidney cancer can have symptoms such as back pain and bloody urine, it's difficult to detect early, said Lee, who said about half of these tumors are found when people undergo X-rays for other reasons.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes no sources other than the surgeon who developed the technique. The story would have been much improved by including some perspectives from surgeons who do not have something to gain by what is said about the technology.", "answer": 0}, {"article": "Nivolumab blocks a T cell inhibitory signaling pathway known as PD-1 that controls the immune response and can prevent the immune system from attacking cancerous cells. The drug is approved for metastatic melanoma patients who show no response to other treatments and for advanced squamous non-small cell lung cancer (NSCLC) with progression on or after chemotherapy. Based on the CheckMate-025 findings, earlier this month (September 16) the FDA granted Breakthrough Therapy Designation to nivolumab for the potential indication of metastatic RCC. The Breakthrough Therapy designation is intended to expedite the development and review of medicines with early signals of clinical benefit in serious diseases to help ensure patients have access to new therapies as soon as possible.\n\"While these treatments have changed the therapeutic landscape for RCC, they are associated with limited survival following emerging resistance to therapy,\" said Sharma. \"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nFor some patients, even after treatment with nivolumab ended, response to the drug continued. \"The immune system has a memory, so even when treatment has stopped, the body continues to exhibit a long-term response - meaning these patients can live normal lives without progressive disease.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to note that the study was funded by the manufacturer of nivolumab (Bristol Myers Squibb) and that Dr. Sharma is a consultant to the company. This is important context.", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are solicited.\u00a0The only link included to an outside \u201csource\u201d is to the company that sells night milk.", "answer": 0}, {"article": "Rick says she usually sends a specific emoji when she is having a bad day. And he responds by distracting her with something completely different.\n\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\n\"The study is incredibly important ... because it shows brief interventions work,\" says Goldstein Grumet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two expert sources not involved with the study are cited, and we didn\u2019t detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Swedish Study Finds Surgery For Prostate Cancer Better Than Waiting\n\"Our findings show that some tumors that are considered to be low-risk at diagnosis do pose a threat to life, especially if they are not surgically removed,\" the study authors write.\nTwo such studies are underway. Results are some years off. But Smith warns against assuming those results will settle the question of how men with early-stage prostate cancer should be treated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the author of an editorial about the study reported on.", "answer": 1}, {"article": "The Decipher\u00ae Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School. \"The Decipher test's tendency to make the two specialties more concordant in their treatment recommendations provides significant value toward standardizing care for patients.\"\n\"It is notable that while the Decipher test significantly influenced treatment decisions, it did not increase the total number of people receiving adjuvant therapy, suggesting that it helped ensure that the ones selected for adjuvant therapy are the ones most likely to benefit from it,\" said Doug Dolginow, M.D., chief executive officer of GenomeDx. \"As genomic tests like Decipher become used more routinely in urologic cancer patient care, they will have a greater impact on treatment recommendations in clinical practice and allow for better personalization of therapy.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "GenomeDx Biosciences funded the research. The company\u2019s name appears 14 times in the release and its product shows up 29 times.\nBut while the study itself makes detailed and explicit disclosures about funding and potential conflicts of interest (some of the researchers are employees of the company), the news release doesn\u2019t. That\u2019s unfortunate. Prostate cancer is very prevalent, Medicare can\u00a0cover the cost of a Decipher test, and about\u00a0half of men who get prostate cancer are covered by Medicare \u2014 so GenomeDx Biosciences has a lot to gain from more widespread use of its product.", "answer": 0}, {"article": "But not all mothers were equally likely to take folic acid supplements. Those who did were more likely to have attended college, to be nonsmokers, to be first-time mothers and to have planned their pregnancies. The researchers also found that the popularity of folic acid supplements rose as time went on. After the researchers controlled for factors like these, they calculated that taking the supplements was associated with a 39% lower risk of having a child with autistic disorder.\nIt\u2019s unclear how these findings apply to mothers and children in the United States. Autism spectrum disorders are diagnosed much more frequently in the U.S. than in Norway.\nThe raw numbers also showed that women who took extra folic acid were less likely to have kids with Asperger syndrome or PPD-NOS, but when other factors were taken into account, the association was no longer statistically significant and could have been due to chance, the researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Unlike the Reuters Health story (which quoted two independent sources), this one does not include comments from an independent source, just a quote from a journal editorial (and that quote doesn\u2019t directly address the quality of the evidence). The competing CNN.com story (also a blog post), reviewed a day earlier, had three independent sources.", "answer": 0}, {"article": "Zeltiq Aesthetics, based in Pleasanton, Calif., is a cautious wallflower that aims to get the data behind its device approved by the F.D.A. before it makes too rowdy an entrance to the party. Its slogan is \u201cMore Science. Less Fat.\u201d\nAfter reviewing Erchonia Medical\u2019s clinical study, Dr. Brian M. Kinney, a plastic surgeon in Los Angeles, said, \u201cI can\u2019t prove that it works.\u201d His concerns are that the tape measure method of gauging circumferential changes \u201cisn\u2019t consistently reliable.\u201d What\u2019s more, study participants and the placebo group were assessed only two weeks after their last treatment, not long enough to measure adequately whether results last.\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used. Hourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed ten sources\u2013two patients [one with good results, one with poor], one federal spokesperson, and seven doctors. Six of those doctors are not objective due to financial interest in the devices\u2019 efficacy. But one is fully independent. \nWith a story like this, which features new technologies, it\u2019s hard to find sources who know the devices well enough to understand them but have no interest in them. The reporter did a good job with sourcing under these circumstances.\u00a0 ", "answer": 1}, {"article": "The greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption). They saw significant declines in blood glucose and insulin, as well as another indicator of insulin resistance called HOMA-IR. They also saw an increase in HDL, or \"good,\" cholesterol. Those consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL. Those with lower doses of flavanols only saw a significant HDL benefit.\n\"The treatment groups of the trials included in our meta-analysis are primarily dark chocolate -- a few were using cocoa powder-based beverages,\" Lin said. \"Therefore, the findings from the current study apparently shouldn't be generalized to different sorts of chocolate candies or white chocolates, of which the content of sugar/food additives could be substantially higher than that of the dark chocolate.\"\nThe authors acknowledge funding from the National Institutes of Health including the National Heart, Lung and Blood Institute, the American Heart Association, and Pfizer. Co-authors at Brigham and Women's also noted receiving funding from Mars Symbioscience, a research segment of Mars, Inc., which makes chocolate products.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources clear.\nIn addition to Lin and Liu, the study\u2019s other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women\u2019s Hospital.\nThe authors acknowledge funding from the National Institutes of Health including the National Heart, Lung and Blood Institute, the American Heart Association, and Pfizer. Co-authors at Brigham and Women\u2019s also noted receiving funding from Mars Symbioscience, a research segment of Mars, Inc., which makes chocolate products.", "answer": 1}, {"article": "Metformin was developed from the French lilac plant, known in the Middle Ages to control excess urination, a symptom of uncontrolled diabetes. The drug was approved by the FDA in the mid-1990s.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper. \"Almost every epidemiological study I can think of found a decreased cancer incidence in diabetics taking metformin. The reduction is real and ranges from 30 to 70 percent.\"\n\"These patients were not diabetic, so they didn't necessarily have high insulin levels to begin with but lower insulin levels,\" Cantley explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources interviewed \u2013 including one who appears to be independent of this research. ", "answer": 1}, {"article": "Trans fats, also called partially hydrogenated oils, enhance food texture and structure. They were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say. The U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included two independent sources; we did not detect any undisclosed conflicts of interest.", "answer": 1}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses. Modern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness. The breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted. So researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds. These molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources have a vested interest in seeing these technologies come to market. Someone without such interests might have provided a helpful brake on the story\u2019s enthusiasm.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Most doctors opt for screening women for cervical cancer more often than guidelines suggest, according to a new study.\n\u201cNo test is perfect,\u201d said Philip Castle, an HPV expert at the American Society for Clinical Pathology in Chicago. But, he added, \u201ca single negative HPV test is very good at ruling out disease.\u201d\nCastle said there could be a few reasons that doctors opt to screen women more often than is recommended. First, they might not know about the guidelines. But women may also be used to annual testing and ask for it themselves.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert from the American Society for Clinical Pathology was interviewed \u2013 someone not involved in the study.", "answer": 1}, {"article": "The results for both techniques were very positive. At 26 weeks, 61 percent of those in the meditation group reported improvement in the activities they could do, compared with 58 percent in the CBT group and 44 percent of those who stuck to their usual routines. The results for pain improvement were similar, with 55 percent in the meditation group reporting improvement compared with 45 percent in the CBT group and 27 percent in the usual-care group. The numbers were similar when rechecked at 52 weeks.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication. The first group engaged in yoga and mindfulness-based stress reduction (MBSR), which focuses on being aware of and accepting physical discomfort. The second group participated in cognitive behavior therapy (CBT) to change pain-related thoughts and behaviors during eight weekly two-hour group sessions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest don\u2019t appear to be an issue here, and the story includes\u00a0statements from\u00a0an accompanying editorial in JAMA, which was written by experts unaffiliated with the research. This squeaks by as Satisfactory, though it should be noted that most of this material was available via news releases (see below).", "answer": 1}, {"article": "PSA stands for prostate-specific antigen, a substance produced only by the prostate gland and found in the ejaculate. Its purpose is to liquefy the semen to release sperm, freeing them to fertilize an egg. The PSA level, measured in nanograms per milliliter of blood, reflects how much of this antigen is being produced and released into the bloodstream. The larger a man\u2019s prostate, the more PSA is produced, which makes the test very confusing in older men with benign enlargement of this gland.\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer. This rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\n\u201cThis has created a huge dilemma in urology,\u201d Dr. Carter said. \u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources are quoted.\u00a0 ", "answer": 1}, {"article": "The Raw Food diet and low-carb Atkins diet also scored poorly overall and ranked low in categories like \"Best Diets for Healthy Eating.\" The Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss. They also considered how easy each diet was to follow, as well as safety and nutritional value.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is the editor of USN&WR and that comment is lifted directly from the news release. It\u2019s standard journalism practice to have at least one outside expert provide additional context or any opposing views in a news story. Many news organizations require two or three.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job citing varied sources to provide the reader with multiple perspectives on this new breast augmentation technique.\u00a0 The story provides both positive and cautious testimonials from a range of cosmetic and reconstructive specialists, researchers and a patient who had the procedure.", "answer": 1}, {"article": "All three groups published the guidelines online this week in their respective journals: the Journal of Clinical Oncology, Practical Radiation Oncology and the Annals of Surgical Oncology.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing. It's always up for discussion now as to who needs [post-mastectomy radiation therapy].\"\nThe new guidelines help clarify what used to be a gray area, Andrews explained. \"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two experts: One who was involved in crafting the guidelines, and one who was not. More input from independent sources would have made the story stronger, but this is sufficient to merit\u00a0a Satisfactory rating.", "answer": 1}, {"article": "For some, relief was almost instantaneous.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear. Nearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico. Within a couple of weeks, the ugly red rash that had covered 90 percent of her body was almost gone. Even better, she said, \u201cfor the first time I didn\u2019t feel any itch at all.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story fails to tell readers that every statistic and every expert quote is from sources funded by the companies, Sanofi and Regeneron, which are seeking approval to sell dupilumab. Not only were both trials funded by the companies, they largely controlled the writing of the New England Journal of Medicine article, to which the researchers \u201cprovided input\u201d and \u201cfinal approval\u201d of material produced with support from \u201cmedical writers who were paid by the sponsors.\u201d\nIn a startling omission, readers are not told that the lone \u201cindependent\u201d expert receives consulting and speaker fees from Regeneron. The story describes Dr. Mark Boguniewicz as \u201can atopic dermatitis expert at National Jewish Health and the University of Colorado School of Medicine who was not involved with the study.\u201d The story should have reported that Boguniewicz received more than $37,000 from Regeneron for consulting, speaking and travel reimbursements last year, according to Open Payments, a federal web site that collects reports of industry funding of physicians.", "answer": 0}, {"article": "\u2022 have a diagnosis of moderate to severe obstructive sleep apnea\nA clinical trial of Inspire therapy found a 78 percent reduction in the number of sleep apnea events per hour for patients.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that the one study it relies upon as evidence\u00a0for Inspire\u2019s effectiveness was funded by the drug company.", "answer": 0}, {"article": "The FDA recently warned people with peanut allergies to avoid foods containing ground cumin, after traces of peanut powder were found in the ground spice.\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said. It could be several more years before the patch will be available for consumers.\nIn the skin patch trial, the international team of researchers randomly assigned 221 volunteers, ages 6 to 55, to wear a placebo patch or a patch containing peanut protein at one of three doses: 50 micrograms, 100 micrograms or 250 micrograms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does offer the reaction of a credible scientist who is not affiliated with the study. But it contains no information to help the reader assess possible conflicts of interest among the study authors. A MedPageToday story about the same study notes that Dr. Sampson, the lead study author quoted in the story, disclosed a relevant relationship with DBV, the company that makes the patch. The story also offers no explanation of who funded the trial (again, DBV).", "answer": 0}, {"article": "to people who have serious or immediately life-threatening, inoperable melanoma that has spread, who have no alternative treatment options, and whose physicians believe the drug is appropriate. Providence Cancer Center is the only site in Oregon offering compassionate use of the drug. The Northwest's other participating centers are the Seattle Cancer Care Alliance and Swedish Cancer Institute in Seattle, Providence Cancer Center in Spokane, and Multicare Health System in Tacoma.\n\"There is no reason it can't be applied to any of the common tumor types,\" Urba says. \"They all have antigens on their surface that T cells can recognize.\" Ongoing trials are testing ipilimumab with other cancer drugs, in different doses and against different cancers.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer. He says the results highlight the potential for using the same approach to treat other cancers. Already, early studies in patients with lung cancer and prostate cancer have produced positive, though inconclusive results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Story quoted one independent source in addition to one of the study co-authors. ", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say. The drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen. Fenfluramine was taken off the market in 1997 after being linked to potentially life-threatening heart valve problems. But lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\n\nAbout half the dieters who took lorcaserin for a year in the study lost at least 5% of their body weight, compared to 20% of dieters who took a placebo pill. About one in five lorcaserin users lost 10% or more of their body weight, compared to one out of 14 placebo users. People who continued on the drug for two years were able to maintain their weight loss better than those switched to placebo after one year, researcher Steven R. Smith, MD, of the Florida Hospital and the Sanford-Burnham Institute tells WebMD. He says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups. The study appears in the July 15 issue of the New England Journal of Medicine. It was funded by Arena Pharmaceuticals, Inc., which developed lorcaserin. The company hopes to win FDA approval to market the new drug later this year.\n\nDiet Drug Users Lost Twice as Much Weight The study included about 3,200 obese or overweight adults who were randomly assigned to take 10 milligrams of the diet drug or placebo, twice a day for a year. All the participants were counseled about diet and exercise. By the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It identifies conflicts in some cases, but there is no truly independent expert source quoted in the story \u2013 something that was badly needed.\u00a0", "answer": 0}, {"article": "Aug. 15, 2012 -- If you aspire to fatherhood, it might not hurt to go a little nuts. Walnuts, that is.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts. The researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that the study was partially funded by the California Walnut Commission, and it solicits a comment from an independent fertility expert. However, the expert\u2019s comments don\u2019t really add anything in the way of critical evaluation of the research or its implications. His quote\u00a0is generally supportive of the idea that diet plays a role in fertility, but offers nothing specific about the study. He could have been tapped, for example, to evaluate the clinical importance of the results. Tough call, but since he also offers advice suggesting that we\u2019re still a ways away from concrete recommendations regarding walnuts (\u201cFor now, the idea is to eat healthy with a varied diet.\u201d), we\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "Read more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\nThe researchers analyzed existing studies of 21 different drugs, and found some were much more effective than others.\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes from three psychiatrists who were not authors on the study, taken from an online source called Science Media Centre.\nIt doesn\u2019t say that one of them \u2014 Carmine Pariante \u2014 disclosed he received research funding from companies that make antidepressants. Pariante\u2019s quote seems to have provided the basis for the story\u2019s lead, which stated antidepressants \u201creally do work.\u201d", "answer": 0}, {"article": "To answer their question, the researchers followed 4,640 participants from the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study for five years after the conclusion of the trial in 2009. The findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels. However, a randomized study is needed to confirm these findings, according to the authors.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\nWHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of \"good\" cholesterol, despite being treated with statins. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources for the study clear.", "answer": 1}, {"article": "Children whose cords were cut more than three minutes after birth had slightly higher social skills and fine motor skills than those whose cords were cut within 10 seconds. The results showed no differences in IQ.\n\"Polycythemia can have medical consequences for the infant, including blood clots, respiratory distress and even strokes in the worst-case scenario,\" Lorch said. Some studies have found higher levels of red blood cells in babies with delayed cord clamping, but there were no complications.\n\"There is growing evidence from a number of studies that all infants, those born at term and those born early, benefit from receiving extra blood from the placenta at birth,\" said Dr. Heike Rabe, a neonatologist at Brighton & Sussex Medical School in the United Kingdom. Rabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story made very good use of independent sources beyond the study authors.", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"In this phase 2 study, the results are certainly impressive and warrant further investigation,\" Ong said. \"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins. If larger trials and longer durations of observation confirm these initial findings, many patients whose LDL cholesterol are otherwise untreated or under-treated could benefit.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this story includes quotes from experts not involved with the trial (unlike a Reuters story we also reviewed about a different trial of the same drug), it fails to tell readers that:\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 the trial was funded by Amgen\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amgen led the design and conduct of the study\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 key researchers receive payments from Amgen, not only for research, but also to serve on boards and conduct outreach for the company.\nAll of this conflict of interest information is clearly listed at the end of the journal article that reports the trial results. It should have been included in the story.", "answer": 0}, {"article": "PCA3 is found only in the prostate. When prostate cells become cancerous, their PCA3 genes go crazy. Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PCA3 test isn\u2019t a replacement for PSA testing. But it improves the ability to diagnose prostate cancer, Groskopf says.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story mentioned that the study was funded by the company that makes the test in question.\u00a0 The quote from the clinician from a for profit cancer treatment center barely qualified as an independent source. ", "answer": 1}, {"article": "Smoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year. The smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo. \u201cBut the findings from one study do not make a fact. We need more studies, funded by someone other than the company that makes the product.\u201d\nStill, some researchers not involved in the study said the topic required more work.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does clearly state the relevant study was funded by Pfizer \u2014 the drug company that makes Chantix. That\u2019s good. However, the story quotes only three sources. Two of them are authors of the relevant study. The third is David Abrams, who heads the Schroeder Institute for Tobacco Research and Policy Studies. A quick internet search finds that Abrams has also done smoking cessation research with funding from Pfizer. The story would have benefited from input from an expert with no ties to Pfizer\u2019s smoking cessation research.", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Though the story included quotes from the author of a book on probiotics, it failed to include any insight from independent experts. \u00a0It should have included information from experts in the field without an association to a marketable product. \u00a0A link to something like NIH\u2019s site about probiotics would have lent some credibility to the information the story tried to impart.\n\u00a0http://nccam.nih.gov/health/probiotics/\nStating that the FDA is \"neutral\" obscures the fact that foods are not regulated in the same way as drugs.\u00a0 ", "answer": 0}, {"article": "Robert Bush has multiple sclerosis (MS), which sapped his ability to walk five years ago. Joseph McGlynn suffered a stroke that seriously impaired his left side, also five years ago.\nNathan Makowski, an investigator at the Cleveland FES Center, created by Case Western Reserve and the Cleveland VA, said that FES technology has been used primarily for therapy in stroke patients in the past. \"This, though, is a more long-term assistive system,\" he said.\nTwo studies, published in the American Journal of Physical Medicine and Rehabilitation, show that functional electrical stimulation (FES) significantly helped McGlynn and Bush to effectively walk at the medical center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note the funders but they are listed on the sidebar of EurekAlert!, a host site for the news release.", "answer": 1}, {"article": "Ferrets are next, then possibly humans\nIn the new study, the peptide was delivered to mice through their noses, where flu viruses were also delivered.\n\"The peptide described in the Immunity report is somewhat unusual because of the apparent specificity,\" Rollins-Smith said about how urumin specifically targets H1 viruses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The primary source is clearly linked to the study, and two other sources are identified as independent of the research. Although the story does not mention funding sources, a news\u00a0release describing the research indicates that funding came from the university itself, not from external sources.", "answer": 1}, {"article": "Gloucester Pharmaceuticals, which won approval in November for a drug to treat cutaneous T-cell lymphoma, another rare cancer, declined to discuss what it would charge when that treatment, called Istodax, goes on sale in January.\n\u201cIt\u2019s a two-edged sword that we have to live with and deal with,\u201d said Louis J. DeGennaro, chief scientific officer of the Leukemia and Lymphoma Society, which has received donations from Allos and other companies. \u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple stakeholders, including experts from the drug manufacturer, a large\u00a0insurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue.", "answer": 1}, {"article": "Do not try the immunotherapy technique at home; these experiments are conducted under medical supervision.\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said. But only one-third have longterm protection. Others need regular exposure to milk in order to maintain protection against allergic reactions.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There wasn\u2019t any independent voice in the story.", "answer": 0}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nAn analysis of data combined over multiple U.S. health plans showed approximately 50 percent of patients discontinue oral bisphosphonate therapy within the first year, Amgen said.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "WASHINGTON (Reuters) - Commonly used diabetes drugs such as metformin may help control lung cancer, and may help prevent it, U.S. researchers reported on Tuesday.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Is it an independent source if the quote is copied from the press release? Perhaps that\u2019s a philosophical question. We gave it a pass on this one because we\u2019ve already dinged the story for relying too much on a news release in the criterion above.\nWe\u2019re given affiliations of the lead investigator and ACCP president. But it\u2019s unclear from the abstract whether A)\u00a0conflicts of interest were never disclosed by the researchers or B) that Dr. Mazzone disclosed that he had none. We\u2019re not told about the other authors\u2019 disclosures. From here we see no relevant problems, but it\u2019s another consequence of unpublished research: once it\u2019s peer-reviewed and published, we\u2019ll get clear, direct, and complete information about author conflicts of interest and study funding.", "answer": 1}, {"article": "First published on October 29, 2009 at 12:00 am\nThe study, known as DPPOS, puts science behind Mr. Held's success. For 10 years, researchers tracked 2,766 people nationwide with pre-diabetes -- a metabolic condition featuring slightly elevated blood-glucose levels that often serves as a precursor to type 2 diabetes.\nStudy participants, who still undergo physical screening twice a year, show benefits, even for those with a weight loss of only 5 pounds. Most initially lost 15 pounds before regaining some of the weight.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter spoke only with two study participants\u2013an area man who was a subject and a researcher who headed local efforts.\nThe local researcher does offer properly moderated comments, casting the study as suggestive of benefits under certain conditions.\u00a0 \nThis is a good start for sourcing but insufficient. At minimum the reporter should have spoken with one disinterested diabetes or obesity clinician or epidemiologist who could help put the findings in context.", "answer": 0}, {"article": "TAMPA, Fla. (July 17, 2017) - Moffitt Cancer Center researchers launched a first of its kind study comparing the long-term benefits of radiation therapy in women with breast cancer either before surgery (neoadjuvant) or after surgery (adjuvant). Their study, published in the June 30 issue of Breast Cancer Research, found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy. This was true for patients who underwent both partial and complete mastectomies. The researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were noted and do not appear to be a conflict of interest.", "answer": 1}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert who wasn\u2019t involved in the current study. However, since the source is involved in the development of a competing \u201celectronic nose\u201d technology, we don\u2019t think he qualifies as a truly independent voice.\u00a0Someone with expertise evaluating cancer screening evidence could have probably provided more useful context for readers.", "answer": 0}, {"article": "The results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%. This means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\nDr Markar said: \"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals. This study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not. However, these findings must be validated in a larger sample of patients before the test could be used in the clinic.\"\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are named in a sidebar to the release on the EurekAlert! website. Ideally, the funders would also be listed in the release text so that when the release is republished that information is available.\nThe study abstract noted that the researchers stated they had no conflicts to declare.", "answer": 1}, {"article": "\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence. CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\n\"The study results show that CAM2038 provides rapid and extended blockade of opioid effects,\" said Fredrik Tiberg, President and CEO of Camurus. \"The results also confirm the dose selection in the current Phase 3 program and the potential of CAM2038 as a future treatment alternative for patients with opioid use disorder, from initiation to long-term maintenance.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No mention is made of funding, and the roles of the two academics quoted are never made clear. We are not told whether they helped carry out the study itself, whether they have a financial interest in the product, or whether they are speaking as disinterested expert observers.\nAccording to a speakers bio for a conference on treating opioid addiction, one of the experts quoted has financial ties to the sponsors of the drug tested. This conflict of interest should have been mentioned in the release.", "answer": 0}, {"article": "Charles H. Hennekens, MD, is professor of medicine at Florida Atlantic University. He was the principal investigator of the Physician\u2019s Health Study, which was the first to demonstrate that aspirin prevents a first heart attack in men, and the Women\u2019s Health Study, which was the first to demonstrate that aspirin prevents a first stroke in women.\nSome healthy men and women should take aspirin every day to ward off heart attack, stroke, and colorectal cancer. That\u2019s the final recommendation from the US Preventive Services Task Force (USPSTF) after more than a year of study and lively public comment. The recommendations were published Monday in the Annals of Internal Medicine.\nMany patients \u2014 and many health care providers \u2014 believe that the aspirin-for-primary-prevention issue is settled. Not so. In fact, several clinical trials now underway are looking at this very question. These include the ASCEND, TIPS-3, and ASPREE trials.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We applaud the breadth of sourcing in this piece. Readers are told that Kirsten Bibbins-Domingo, is the\u00a0vice-chair of the US Preventive Services Task Force, and she weighs in with her assessment. \u00a0Other physicians, however, seem independent of the USPSTF and are unlikely to be financially conflicted with the manufacturers of aspirin.", "answer": 1}, {"article": "Easier To Take, More Impact\nDr. John Richert, executive vice president of research and clinical programs at the National MS Society, says the introduction of these pills will mark a major improvement in the lives of MS patients.\nThis week's issue of The New England Journal of Medicine reports on two new drugs that can be taken orally to slow the progress of MS. The studies for these drugs, which are not yet on the market, were funded by the drug manufacturers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used one independent expert source in addition to interviewing one of the study authors. ", "answer": 1}, {"article": "She agreed to the memory testing for the study. \u201cIt was a little humiliating, to be honest,\u201d she said of the testing. \u201cI would remember one or two items from a list of objects in a kitchen, for instance, then think, \u2018Oh no, what else was there?\u2019 \u201d\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state. \u201cThe average enhancement effect was about 12 to 13 percent,\u201d Dr. Kahana said. \u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation. The preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable. Many of the electrodes sit in or near memory areas, and the wait can take weeks in the hospital. Cognitive scientists use this opportunity, with patients\u2019 consent, to present memory tests and take recordings.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The end of the scientific article that this story was based on notes that the two\u00a0senior authors are forming a company \u201cto develop and commercialize brain stimulation therapies for memory restoration.\u201d This should have been included in the story.", "answer": 0}, {"article": "Recognizing that need, the AHA says it is considering re-evaluating all its dietary recommendations, and will make the issue of polyunsaturated fats part of this assessment. Reviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits. When health organizations advised people to lower their intake of saturated fats, for example, many replaced the fats with carbohydrates, which can increase risk of diabetes and lead to higher levels of another type of fat in the blood, triglycerides. \u201cOne of the things we learned is that we need to look at the whole picture,\u201d says Lichtenstein. \u201cJust looking at one individual component puts undue emphasis on that component, and may lead to unanticipated consequences. We need to look at dietary patterns rather than individual nutrients or individual food components.\u201d\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\nA study shows that not all good fats are the same when it comes to protecting your health\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a comment from an American Heart Association spokesperson, who interestingly suggests that the new research may play a role in a re-analysis of the organization\u2019s diet guidelines. That\u2019s different than the stance taken by\u00a0the spokesperson contacted by HealthDay, who hinted that the results wouldn\u2019t have much effect on current recommendations.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.\n\u201cLabor pain matters more than just for the birth experience. It may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study. \u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the study.", "answer": 0}, {"article": "[1] http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61117-5/abstract \n\"This both historical and innovative trial was made possible thanks to exemplary international collaboration and coordination, the contribution of many experts worldwide, and strong local involvement,\" said Dr John-Arne R\u00f8ttingen, Specialist Director at the Norwegian Institute of Public Health, and the chairman of the study steering group [4].\n[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus. \n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies the funding sources for the study, which included WHO and a number of government agencies from Canada, the United Kingdom, Norway, along with the international organizations the Wellcome Trust and M\u00e9decins Sans Fronti\u00e8res. The news release also identifies the organizations with which the study\u2019s research team members were associated, although it does not give any indication of the extent to which research team members or their organizations receive additional funding from Merck, which obviously stands to gain the most if the vaccine proves effective and is recommended for use by the World Health Organization.", "answer": 1}, {"article": "The idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product. Since dermatologists also know about hair, the company consulted him. Why, Dr. Anderson asked the company executives, couldn\u2019t there be a polymer to put on skin?\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly uses sources beyond those provided by the news release. It also gets applause for pointing out clearly the connection between the researchers and the companies licensing the product saying, \u201cAll of the authors on the new paper have an equity interest in Living Proof and so, indirectly, in Olivo,\u201d (the two identified companies).\u00a0 NBC\u2019s story on the same research\u00a0didn\u2019t\u00a0make this financial connection nearly as clear.", "answer": 1}, {"article": "\"I do consider this a proof of the principle that it can work,\" Rosenberg said yesterday. \"I have every expectation that we can get it to work better.\"\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\n\"I think it is an important landmark to see some cancer patients respond to a gene therapy -- finally,\" said Patrick Hwu, a physician and gene-therapy researcher at the University of Texas M.D. Anderson Cancer Center, in Houston, who was not involved in the new study. \"I think that clearly all of us want to do better than two out of 17.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This article included helpful comments from clinicians familiar with the experimental approach but who were not directly involved with this particular study. They help to temper the enthusiasm of the principal investigator on this project and to balance the piece.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies the lead author of the study when quoting him and cites two additional experts who have no affiliation with the study.", "answer": 1}, {"article": "The result: The relative risk for squamous cell carcinoma was found to have dropped by 15 percent among those Danes who had filled more than two NSAID prescriptions, compared to those who had filled two or less.\n\"Our study showed that users of common painkillers, known as NSAIDs, have a lower risk of the three major types of skin cancer, [including] malignant melanoma, basal cell carcinoma and squamous cell carcinoma,\" said study lead author, Sigrun Alba Johannesdottir, at the department of clinical epidemiology at Aarhus University Hospital in Aarhus, Denmark.\nThe researchers pointed out that the NSAID-cancer connection could be affected by a range of lifestyle factors they did not account for, such as an individual's specific skin type or sun exposure patterns.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert was quoted, although unfortunately his comments tend to reinforce the story\u2019s exuberance rather than restrain it. Why this private practice dermatologist was chosen as the one independent expert is unknown.\u00a0 Does he have a research background?\u00a0 The quote doesn\u2019t offer any evaluation of the evidence.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story references a written editorial published to accompany the story in JAMA, which we\u2019ll consider good enough for a satisfactory rating here. Actually interviewing someone not affiliated with the research might have yielded additional interesting insight on this topic.", "answer": 1}, {"article": "Provenge from Dendreon, by contrast, trains the patient\u2019s immune system to attack the tumor. The drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\nDrugs now used to treat advanced prostate cancer, like Taxotere, do not have much affect on bone scans, Dr. Smith said. Bone drugs like Zometa from Novartis and denosumab from Amgen can protect cancerous bones from fractures, but have not been shown to fight the cancer itself.\nAnother investigator in the trial, Dr. David C. Smith of the University of Michigan, said he could not believe it when the bone scan of one patient, who previously had widespread cancer in his bones, came back completely clean.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted at least one clinical expert who did not appear to have ties to the study reported on or the company that makes the drug. It would have greatly improved this story if insight from an expert on prostate cancer, especially castration-resistant prostate cancer had provided a context for evaluating the benefit of the drugs reported on \u2013 including quality of life issues.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not provide any independent input about the therapeutic claims of rivastigmine for treating dementia in people with Parkinson\u2019s. ", "answer": 0}, {"article": "U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\n\u201cYou couldn\u2019t design something better for the criminal justice system,\u201d said David Farabee of the University of California at Los Angeles, who leads a Vivitrol study in a New Mexico jail. \u201cThere\u2019s been pushback with other medications, people saying, \u2018We\u2019re just changing one drug for another.\u2019 That argument goes out the window when you\u2019re talking about a blocker\u201d like Vivitrol.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The company that owns Vivitrol is clearly identified, as are a couple of sources who are studying the drug, including the first author of the NEJM study. At least one source, who expresses concern about the company\u2019s vigorous marketing to prisons, appears to be independent. The National Institute on Drug Abuse, which supported the research discussed in the NEJM article, is also identified.", "answer": 1}, {"article": "VVA is a chronic condition associated with genitourinary syndrome of menopause (GSM). VVA affects 50 to 70 percent of post-menopausal women, and is characterized by pain with sexual activity, dryness, and discomfort. Current on-the-market treatments for VVA include both over-the-counter creams and moisturizers as well as several safe and effective prescription treatments in cream, tablet, ring or oral form.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms. Though they may suffer from physical and emotional pain as a result of VVA, women may not feel comfortable discussing these symptoms with a healthcare professional, may not recognize the symptoms as treatable, may not fully understand the treatment options available, or if they did receive treatment, found the current prescription treatment options inconvenient, messy, or uncomfortable to use.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis. \"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that Dr. Sheryl Kingsberg, the study\u2019s first author, has been a consultant for TherapeuticsMD, which manufactures the active ingredient in the softgels, and for a number of other pharmaceutical companies. It did not mention that several of the study\u2019s other authors also have received research support or consulting fees from TherepauticsMD.\nThis study carries a strong imprint of its funder, the manufacturer. The acknowledgement in the study notes that even the authorship of the paper was contracted out to a professional medical writing firm, which is a practice that is often criticized. The journal manuscript acknowledged it; the news release could have as well.", "answer": 0}, {"article": "Almost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine. Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study raises many questions that will likely be debated for years by the experts. The failure to provide a single independent voice to the discussion is curious to say the least.", "answer": 0}, {"article": "There was also an 18% reduced risk of dying from any cause over the 20-year period.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t note how the study was funded through Sanofi, a company that makes, markets, and sells statins, Furthermore, most of the authors disclosed that they have accepted either grant money or fees from major pharmaceutical companies. In fact, five out of the the eight authors had or have a financial relationship with Sanofi.", "answer": 0}, {"article": "CHICAGO \u2014 A migraine pill seems to help alcoholics taper off their drinking without detox treatment, researchers report, offering a potential option for a hard-to-treat problem.\n\"You can come in drinking a bottle of scotch a day and get treatment without detox,\" said Dr. Bankole Johnson of the University of Virginia, who led the study, which was conducted at 17 U.S. sites from 2004-2006.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Experts in the field who were not associated with this study were quoted in the story.\u00a0 In addition, the story clearly indicated that the study was funded by the maker of the drug.", "answer": 1}, {"article": "However, they were 3.8 times more likely to experience a serious adverse event, such as an infection, falls, nervous system or psychiatric disorders, or a problem with the device. Forty-nine of the deep brain stimulation patients, or 40%, had 82 serious adverse events, compared with 11% of the drug patients, who had 19 serious adverse events.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nThe problem with deep brain stimulation is that many doctors are not aware of its benefits or don't know how to determine the appropriate patients based on risks vs. potential benefits, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed one patient with a self-reported positive outcome, and four medical specialists. \nThe reporter\u2013eventually, in the last phrase of the story\u2013mentions that the research was paid for partly by the maker of the deep-brain stimulation device.\u00a0 \nOn balance, the sourcing of this story is acceptable.\u00a0 ", "answer": 1}, {"article": "Moderate-intensity exercise, like leisurely bike riding or brisk walking, was associated with an even greater reduction in risk. The authors say that improving doing more light and moderate physical activity could be almost as effective as rigorous exercise at preventing disease and prolonging life. \u201cThe paradigm needs to shift when we think about being active,\u201d says senior author Andrea LaCroix, professor of family medicine and public health at the University of California San Diego.\nFor the study, LaCroix and her colleagues asked 6,000 women, ages 65 to 99, to wear activity-tracking accelerometers for seven days as they went about their daily activities. The women were then followed for an average of three years.\nThe researchers hope their work sparks more discussion about how people\u2014especially older ones\u2014think about exercise and their goals for being active. \u201cI think the current guidelines are discouraging to older people who don\u2019t believe they can do 150 minutes of hard exercise,\u201d LaCroix says. \u201cThey throw up their hands and think, \u2018that\u2019s not for me.\u2019 But everyone does light physical activity, and the idea that doing more of it can have substantial health benefits should be welcome news.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside sources are cited in the story, nor does the story make clear who funded the research (addressing potential conflicts of interest).", "answer": 0}, {"article": "Coffee or tea? There's a growing body of research to suggest that both are probably good for you.\n\nWe've heard a lot about the health benefits of tea, especially green tea. It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects. Good clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\n\nThat's why I was so interested in a report last week in the Journal of the American...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotes from any investigators in the field. Even if Dr. Weil\u2019s expertise is taken into account as author of the piece, that is still only a single-source perspective. ", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted sources beyond only the study authors. Some of the study authors disclosed relationships with medical device companies such as Boston Scientific (which makes the Watchman device mentioned in the story); however, a quick search did not reveal any conflicts of interest for Drs. Giri \u00a0and Koren, the two expert sources who are directly quoted by the story.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is an inherent weakness of this sort of first-person reporting that there is an absence of independent sources. All but one of the physicians quoted in the story were personally involved in the reporter\u2019s case. The one exception is a vascular surgeon who strongly advocates for broader carotid artery screening. There are no quotes from experts who were members of the task force that recommended against widespread screening.", "answer": 0}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects. New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms. In addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nTarleton and colleagues say the next step is to see if their promising results can be replicated in a larger, more diverse population.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release didn\u2019t mention either the funding sources or address conflicts of interest. These were noted in the study and could have been easily included in the release.", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, it should have been made clear that the May 2018 \u201clarge-scale test\u201d is unpublished and funded by the test sponsor.\nThe same goes for the Genecept paper that is cited by the company\u2019s VP: it\u2019s an industry-sponsored review paper \u2014 not original research \u2014 and cannot\u00a0 make claims about improved clinical outcomes or reduced overall medical costs from genetic testing.\nWe were pleased to see two independent sources cited, one of which provided a critical perspective.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This one barely squeaks by. There is one independent comment on the trials from\u00a0David Felson at the Boston University School of Medicine, who said that the lack of a control group \u201craises questions of whether it is cupping that is really working or if it has a placebo effect.\u201d But more detailed comment on each of the cited studies\u2019 shortcomings and limitations would have been hugely helpful in producing a more balanced view on the benefits of cupping.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies sources affiliated with the two companies that make the radiation device, as well as a researcher who is funded by one of the companies. \u00a0These sources are offset by references to the JAMA Dermatology editorial and by comments from one of the editorial authors.", "answer": 1}, {"article": "He then wanted to show us that radio waves are harmless to humans, and even moved his hand back and forth into the force field. \"Nothing happens,\" he told Stahl.\nKanzius thought he had discovered a way to attack cancer cells without the collateral damage caused by standard treatments like chemotherapy and radiation. \"I said 'Eureka, I've done it,'\" Kanzius remembered.\nJohn Kanzius Research Foundation: Learn more about the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThat journalists with the resources and airtime available to \u201c60 Minutes\u201d failed to present any independent experts or even to let viewers know about the patent and other financial interests of the people interviewed is just mind-boggling. Given the fact that there are literally thousands of scientific articles on related topics, it is mystifying that Stahl failed to present an iota of context or perspective from anyone without a personal stake in the device. (The comments of the pathologist in the piece don\u2019t count, since he had no way of knowing whether the blood cell counts he looked at displayed the effects of Kanzius\u2019s device or merely the expected results of chemotherapy.)\n It is impossible to watch this story without reaching the conclusion that Stahl and the producers made a conscious decision to exclude any independent experts.", "answer": 0}, {"article": "To some, this kind of fat recycling seems simple. But Dr. Michael F. McGuire, the president of the American Society of Plastic Surgeons, cautioned: \u201cHow you take the fat, how you process it, how you inject it are all factors in how successful fat survival is going to be.\u201d\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years. (For weeks, participants wore a cumbersome bra-like tissue expander at night that was created by Dr. Khouri to create a scaffolding for their fat.) The study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\nLast month, new guidelines from the recommended that most women should start mammograms at 50, instead of 40, to try to reduce the number of tests, including biopsies for false positives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story included more than one independent expert and it identified the professional affiliations and some of the financial arrangements between experts who were quoted and companies or practices that profit from fat grafting.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any experts who could have provided some valuable perspective on the importance of the new findings. This is particularly important for industry sponsored trials.\u00a0 ", "answer": 0}, {"article": "Besides being linked to chronic, severe gum disease, this type of bone loss has also been connected in rare cases to the use of bisphosphonates, a different class of osteoporosis drugs.\n\"I think that it's really an important important proof-of-concept that you can inject locally and get a response,\" said Dr. Rena D'Souza, chair of biomedical sciences at Texas A&M Health Science Center Baylor College of Dentistry in Dallas. \"We could not only use this approach for the treatment of periodontal disease where the disease enters the bone and gum. but also other forms of periodontal disease.\"\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites the editorial and one source who seems independent. It fails to mention that Forteo\u2019s dad, Eli Lilly, provided financing for this study, and one author disclosed an additional financial relationship with Lilly.\n More of the perspective from the editorial would\u2019ve been a great asset to this article, as it provided a realistic appraisal of the study\u2019s results.", "answer": 0}, {"article": "Dr. Auwerx attributes this change in large part to the significantly increased number of mitochondria he detected in the muscle cells of treated mice.\nDr. Evans described the study as \u201cvery important, because it is rare that we identify orally active molecules, especially natural molecules, that have such a broad-based, positive effect on a problem as widespread in society as metabolic disease.\u201d\nDr. Auwerx\u2019s study complements one published earlier this month by Dr. David Sinclair of the Harvard Medical School, who found that much more moderate doses of resveratrol protected mice from the metabolic effects of a high-calorie diet. Though his mice did not lose weight, they lived far longer than undosed mice that were fed the same high-calorie diet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story quoted several scientists not directly associated with the particular studies or companies mentioned, there was no balance to the perspectives represented.\u00a0 The story would have been greatly imporved if it had included some serious comment about the ramifcations of the scientific observations reported.", "answer": 0}, {"article": "LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's most comprehensive health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSU Health New Orleans research enterprise generates jobs and enormous economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www. , http://www. or http://www. .\n\"This study is one of the largest breast anthropometry (measurement) studies ever performed,\" says Lau. \"These results help us provide the best breast reduction outcomes to our patients.\"\n\"Breast reduction is one of the most commonly performed plastic surgery procedures. The long-term appearance after reduction is not optimized 50% of the time using standard reduction techniques,\" notes lead author Dr. Frank Lau. \"At LSU Health New Orleans, we offer an improved technique that preserves more of the critical breast anatomy. This study provides an anatomical foundation for why our technique may yield better, longer-lasting results.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention a funding source but that\u2019s understandable since the published study clearly states there is no conflict of interest and no funding source.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research. \u201cIt would cost less than 5 pence ($0.07) per customer \u2014 not much different to a sachet of ketchup.\u201d\nFrancis\u2019 team \u2014 who worked independently and had no funding from the drug or food industries for their research \u2014 used data from a previous large study to quantify how a person\u2019s heart attack risk increases with their daily intake of total fat and harmful trans fats.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The use of independent voices here is key, and the reporting team did a lot of reading to give readers a fuller picture of the debate about statins. If people could hear more doctors saying that a particular drug is \"not a magic bullet\" in news stories, we probably would pay far less for the drugs that do work well.", "answer": 1}, {"article": "The incidence has more than doubled in developed countries in recent decades. More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed. The author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish. Pregnant women are generally advised to limit their consumption of certain types of fish like swordfish and tuna because they contain mercury. But many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly explains who funded the study, and includes an independent source. But it doesn\u2019t note the extensive conflicts of interest reported by the lead author who\u2019s quoted in the piece:\nDr. Bisgaard reports receiving consulting fees from Chiesi Pharmaceuticals and Boehringer Ingelheim, and Drs. Bisgaard and B\u00f8nnelykke report being named on a pending patent related to the prevention of childhood asthma through FADS genotyping and the assessment of blood levels of eicosapentaenoic acid and docosahexaenoic acid in pregnant mothers.\nThe patent filing related to genetic testing is particularly relevant, given that the researcher advocates genetic testing and testing of fish oil levels in pregnant women to determine who might benefit most from supplementation.", "answer": 0}, {"article": "Women who carry these mutations have a lifetime risk of breast cancer of anywhere between 56 percent to 84 percent, according to the researchers, whereas the risk for ovarian cancer ranges from 36 percent to 63 percent for BRCA1 mutation carriers and 10 percent to 27 percent for BRCA2 mutation carriers. By contrast, the lifetime risk of breast cancer among women generally is about 12 percent, and for ovarian cancer, it's less than 2 percent.\n\"This is a very important study because it gives us more information in order to counsel women at risk,\" said Dr. Daniel Silver, assistant professor of medicine at the Dana Farber Cancer Institute and Harvard Medical School. Silver added that women who are found to carry one of these genetic mutations face \"a very complex set of considerations, so the more hard facts you can give them, the better.\"\n\"One of the main messages of our study is that salpingo-oophorectomy should be part of any management plan for any woman who is found to have these genetic mutations,\" said Rebbeck. \"There really isn't anything else that can reduce a woman's risk by this much.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal who was not involved in this study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper. \u201cThis is a simple dietary change that we believe most women can understand and adopt. It may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program. \u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly stated at the end of the press release. There are no apparent conflicts of interest.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have brought in some independent voices, which is why we gave it an unsatisfactory here. It did note that one of the authors had been a paid consultant for the pharmaceutical industry and for Weight Watchers, which was good to see disclosed.", "answer": 0}, {"article": "Update| Anyone who\u2019s ever dieted knows that sorting through the deluge of research can be overwhelming. Paleo has a devout following who swear by its protein-heavy meals, while intermittent fasters believe that forgoing food for hours on end (which varies, but can include skipping meals for an entire day), provides the best results. For those who just can\u2019t give up grains (or regular eating), a new study indicates that being less restrictive is actually better for your waistline.\nFor the small study just published in the International Journal of Obesity, the team enlisted 51 obese men from the ages of 25 to 54 years old. All participants had maintained their current weight for six months leading up to the study and did not exercise regularly. One group of men followed the diet, which reduced calorie consumption by about one-third of their individual needs, for 16 weeks straight. The experimental group stuck to the eating plan for two weeks, before ditching the diet for two weeks. They repeated the cycle until they had also dieted for 16 weeks; however, in their case, each bout of restriction was followed by a period of eating enough calories for weight maintenance.\nKrista Varady, an outside researcher who studies intermittent fasting (not the same as intermittent dieting) and weight loss at the University of Illinois, believes the results were significant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included an \u201coutside researcher\u201d who has some bona fides in the study of intermittent fasting, albeit not dieting, and quotes her essentially saying that the findings were significant and made sense to someone who studies dieting challenges.", "answer": 1}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\" It was originally a defense mechanism found in bacteria that allows the bacteria to recognize and slice up the DNA of invading viruses. Scientists have learned how to manipulate this mechanism so that it essentially can be programmed to find and remove a specific sequence of DNA code--which acts like software for controlling biological activity in a cell. Cas9 is a reference to an enzyme, sometimes described as a form of \"molecular scissors,\" that is used by CRISPR to cut out a section of DNA code.\n\"We think it's best to start with CRISPR therapies that involve relatively conservative uses of this powerful tool,\" Dr. Kmiec said. \"This approach can also hopefully help contain costs and provide a level of safety and reliability that is reassuring for patients and increases the chance that insurance companies will provide coverage.\"\nDr. Kmiec noted that while his team is working to move into human trials, the CRISPR application being developed for lung cancer does not involve directly editing a patient's genome --only the genes in the tumor.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders (NIH and State of Delaware) are noted on a sidebar on the EurekAlert! site which hosts the release. We encourage news release authors to include funding sources in the body of the release as well.\nThe authors did not report any conflicts of interest.", "answer": 1}, {"article": "A treatment for obesity could be on the horizon as scientists have discovered an antibody that reduces body fat.\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nBut how do mice models translate to human treatments? Mice a fairly close genetic match to Humans, and Zaidi is hopeful there will be similar effects in humans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite one independent source, but only in the very last paragraph. The story does not tell readers who funded the research, nor does it note that a provisional patent has been filed for the antibody. This is particularly relevant given that the scientist listed as inventor on that patent, and who would therefore receive royalties and/or licensing fees if the antibody is commercialized, is the same researcher who is quoted throughout the article about the potential impact of the antibody.", "answer": 0}, {"article": "April 21, 2010 -- An experimental oral drug is showing early promise for the treatment of chronic hepatitis C virus (HCV) infection, a study shows.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "According to disclosure statements from a 2008 CME program,\u00a0Dr. Bruce Bacon, an expert source for this story, received research funding from Bristol Myers Squibb, which is developing the experimental drug being discussed. He also is a consultant to drug companies developing competing drugs for hepatitis C.\u00a0To avoid the appearance of a conflict of interest it is desirable to identify\u00a0relationships such as these clearly.\u00a0 This story fails to do so.", "answer": 0}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard. And he didn't want to give it all up due to a \"spot of pain\" in his elbow. \"This wasn't a traumatic injury,\" explains Holzman. It came on gradually and escalated from annoying to excruciating over the course of a couple months.\nWhen Holzman came to Sport & Spine for help, Bishop put him through a series of traditional treatments including ultrasound, strengthening and stretching exercises, cross-friction massage, heat and ice.\nNot all physical therapists are sold on the FlexBar. \"There's a variety of methods you can use to achieve the strengthening technique,\" says Jason Grandeo, a physical therapist at Body Dynamics, Inc. in Arlington, Va.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes the involvement of the FlexBar manufacturer in the study that is referenced.\u00a0It also quotes an independent\u00a0physical therapist who suggests there are other ways to achieve the effect attributed to the FlexBar.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the lead author of the recent study, Claudia Henschke. The story should have quoted other clinicians or researchers who could have provided some much needed balance.", "answer": 0}, {"article": "This is not the only significant study Professor Elwood led research examining ways to improve peoples' health. In 1974 Elwood's team reported the very first randomised trial of aspirin in the prevention of vascular mortality in the British Medical Journal.\n\"There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,\" said Professor Peter Elwood who led the research published in the journal PLOS ONE.\n\"One of the concerns about taking aspirin remains the potential for intestinal bleeding. That's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data. In no study was serious or life-threatening bleeding reported.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and potential conflicts of interest weren\u2019t noted in the release. The study, published in PLoS ONE,\u00a0 however, declares no conflicts of interest and \u2014 curiously \u2014 no support or funding, either.\nBut since this type of study is based on analyzing others\u2019 results, we\u2019ll go out on a limb to assume that the researchers\u2019 institutions backed it in the form of their usual salaries. In any case, we want to see these items clarified in news releases.", "answer": 0}, {"article": "The most common side effects from Suvorexant have been headache and sleepiness. No serious drug-related side effects have been reported.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does report that the researchers work for Merck, the company applying for approval to sell a similar drug. The story would have been better if it had included comments from an interview with an independent source (as did the HealthDay story we also reviewed), rather than just an excerpt of a journal commentary article.", "answer": 1}, {"article": "UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years. \"People thought we were absolutely crazy to launch this trial, because they thought that only in newly diagnosed cases could a drug like this be effective -- intuitively, if myelin damage is new, the chance of repair is strong. In the patients in our trial the disease had gone on for years, but we still saw strong evidence of repair.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that work was funded by the Rachleff Family.\nHowever, five out of 18 authors, including the first author, had multiple competing interests, mostly in the form of personal and consulting fees from the world\u2019s largest pharmaceutical companies according to the original journal report. Those conflicts should have been mentioned in the news release.", "answer": 0}, {"article": "The next step was to ask whether those variants really could predict who had prostate cancer. So Dr. Jianfeng Xu, a professor of epidemiology and cancer biology at Wake Forest University School of Medicine, and his colleagues studied a Swedish population of 2,893 men with prostate cancer and 1,781 men who did not have it. That led to their finding that each of the five variants independently predicted prostate cancer risk.\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said. Still, he said the new test could help patients if it was used with caution. \u201cWe may be premature with this idea \u2014 everyone has a different way of thinking about this \u2014 but it should not take five years to know if we are on the right track. All this can happen very rapidly.\u201d\nThe study, by scientists at Wake Forest University School of Medicine, the Karolinska Institute in Sweden, the Harvard School of Public Health, and Johns Hopkins Medical Institutions, will appear in the Feb. 28 issue of The New England Journal of Medicine. It was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from experts in the field who were not connected to the study reported on.", "answer": 1}, {"article": "In the meantime, fish is \"a good prescription for other things and we have a hint it might be helpful for the brain,\" Scarmeas said.\nThe researchers took into account various health and lifestyle factors, including age, education and body mass index, to explore whether other differences among the people with low levels of omega-3s could help explain their more rapid brain aging.\nFor the study, researchers measured the red blood cell level of fatty acids in 1,575 dementia-free people whose average age was 67. About three months later, participants underwent mental-functioning tests and MRI scans that examined brain size and blood supply in the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert, and there were no conflicts that should have been identified.", "answer": 1}, {"article": "More than 400 million people worldwide report episodes of depression, at a global cost of around \u00a3600bn in 2010. Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nReturning to the women and their children seven years later, researchers found that the treated mothers were still significantly less likely to be depressed than the control group. The first group were also more likely to be employed and have control over household spending. There were also big improvements in their parenting style.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote anyone independent of this study; this would have been very useful to include considering this is unpublished data (as far as we can tell).", "answer": 0}, {"article": "Many women have been reluctant to use hormones for menopause symptoms since 2002, when the federally funded Women\u2019s Health Initiative (WHI) study linked the treatments containing man-made versions of the female hormones estrogen and progestin to an increased risk of breast cancer, heart attacks and strokes.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and there does not appear any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Bret Stetka is a writer based in New York and an editorial director at Medscape. His work has appeared in Wired, Scientific American and on The Atlantic.com. He graduated from University of Virginia School of Medicine in 2005. He's also on Twitter: @BretStetka.\nReferring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease. Unfortunately, [the findings] suggest that the therapy may not be as robust as initially proposed.\"\nNext, Lozano launched a randomized trial involving 42 patients from the US and Canada, all of whom had electrodes implanted in the fornix on both sides of the brain. In half the patients the stimulation was turned on right away. In the other half the stimulation wasn't turned on for a year, though they didn't know it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites multiple sources but fails to mention research funding or potential or conflicts of interest. Notably, it omits the fact that one researcher at the center of this story, University of Toronto neuroscientist Andres Lozano, M.D., has a financial interest in the deep brain stimulation as co-founder and director of Functional Neuromodulation Inc, which makes the deep brain stimulation device.", "answer": 0}, {"article": "Strobe lighting has been shown to reduce levels of the toxic proteins seen in Alzheimer\u2019s disease, in findings that raise the tantalising possibility of future non-invasive treatments for the disease.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The senior author of the study is cited (and\u00a0her quote came from an unattributed news release, see last criterion, below), but so are other researchers. Independent sources appear to have been consulted.\u00a0The story also notes that the author has formed a company to pursue this, which is an important conflict of interest disclosure.", "answer": 1}, {"article": "\u2022 Naproxen ranked the highest for probability for improving function, followed by diclofenac, celecoxib, ibuprofen, and PRP injections.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar. \"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\n\"This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes,\" said lead author and orthopaedic surgeon David Jevsevar, MD, MBA. \"Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies only where the authors work. It does not include the disclosures listed in the journal article. These disclosures should have been included in the news release.", "answer": 0}, {"article": "A lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus. A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\n\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do. A glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow. From there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen. You must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n\nThe fact that recognizing and acknowledging a familiar person is such...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three of the authors of a published study; in addition it contains interview material from a person being treated that had Parkinson\u2019s disease as well as another clinician who did not appear to contribute to this publication.\nHowever \u2013 there was no one with an expertise in the miminally concious state not connected with this particular\u00a0technology in some way who appears to have been interviewed for this story.\u00a0 ", "answer": 0}, {"article": "Careful phase III clinical trials are now needed to confirm the efficacy in humans. Thereafter, any woman who has been tested positive for a BRCA1 mutation could take RANKL blockade as prevention measure to reduce her dramatically increased breast cancer risk. Josef Penninger adds: \u201cThis work is a great example of an international collaboration of many scientists with one grand vision: Prevention of breast cancer. Cancer prevention is one of the key issues we face in medicine today, a world where much fewer women will get breast cancer in the first place. We have also shown that RANKL/RANK are critically involved in sex hormone-driven breast cancer. If the uncovered mechanism indeed works in the prevention of breast cancer in high risk patients, this could possibly be used to prevent breast cancer in general. One door for breast cancer prevention has now been opened and this can be tested very fast.\u201d\nJosef Penninger\u2019s studies at IMBA are largely supported by the 7.4 million US $ \"Innovator Award\" through the \"US Department of Defense\u201d.\nThe present work is the result of international collaboration. Scientists from Austria (IMBA, AKH Wien) participated as well as researchers from the University of Maryland School of Medicine in Baltimore and the University of Maryland-Baltimore County, Baltimore, USA; Toronto, Canada and Barcelona, Spain. See original publication for details.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the research received funding from the U.S. Department of Defense but it doesn\u2019t provide other important information that adds transparency. According to the published study, the Institute of Molecular Bioltechnology has applied for a patent on using RANKL inhibition to block breast cancer and that Amgen, Inc. (the maker of denosumab) provided RANK-Fc and financial support for the study.", "answer": 0}, {"article": "For more information go to GetAwair.com.\n\u201cThe goal for the user is to keep five green dots. As soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\n\u201cLow dry humidity in the winter can make asthma worse and children who have dried mucosa can acquire some nasal infections easier,\u201d Dr. Robert G. Lahita, chairman of medicine at Newark Beth Israel Medical Center in New Jersey, told FoxNews.com. \u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them. Dry air can also exacerbate some illnesses and can be a problem as well.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is satisfactory, but barely. The story does quote a physician with no obvious ties to Awair about how air quality may affect health. What\u2019s not clear is why the reporter chose to spoke to the physician, who specializes in rheumatism, arthritis and related ailments. More importantly, the story is missing any independent sources who can weigh in on Awair, or how effective it may be at reducing any kind of health risk.", "answer": 1}, {"article": "(905) 525-9140, ext. 22863 \nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the Canadian Institutes for Health Research funded the study.", "answer": 1}, {"article": "Take Elliott Francis, 64, who had his second hip replacement surgery in February. Growing up, he was \u201ca jumper and a rebounder,\u201d he said, scooping basketballs off the rim during Roxbury pickup games and later playing in high school and college.\n\u201cThe baby boomer explosion is a big deal in health care,\u201d said ConforMIS chief executive Mark Augusti. \u201cTechnology has to be part of the solution. Baby boomers expect to be more active as they get older and have higher expectations about quality of life in their later years.\u201d\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story admirably reported the generous pay of doctors who do joint replacements: \u201cLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\u201d\nBut the story doesn\u2019t tell readers that the only doctor it quotes \u2014 orthopedic surgeon David Mattingly, M.D. \u2014 has received $160,000 from joint maker DePuy Synthes, a division of Johnson & Johnson, in recent years, according to the database Open Payments.\nIt would have been good to quote a doctor who doesn\u2019t make a living doing these surgeries (e.g. an internist or sports medicine doctor who treats hip and knee osteoarthritis).", "answer": 0}, {"article": "City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as one of only 47 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the world. City of Hope is located in Duarte, California, just northeast of Los Angeles, with community clinics throughout Southern California. It is ranked as one of \"America's Best Hospitals\" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation, diabetes and numerous breakthrough cancer drugs based on technology developed at the institution.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nNow that we have some data separating low-dose from higher-dose aspirin, more detailed research can be undertaken to understand the full value of low-dose aspirin for breast cancer prevention,\" said Clarke.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the sources of funding. It does not address conflicts of interest, but there do not appear to be any relevant conflicts of interest. Still, the release would have been stronger if it had stated that explicitly.", "answer": 1}, {"article": "Furthermore, diets with low inflammatory potential appeared to correspond to lower risk of hip fracture among one subgroup of the study -- post-menopausal white women younger than 63.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\nVedat Yildiz of Ohio State's Center for Biostatistics also worked on the study, which was supported by the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains that the study was funded by\u00a0the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.", "answer": 1}, {"article": "There were no reports of serious adverse side effects. The most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\n\u201cWe are encouraged by these Phase II results showing positive effects of MK-4305 in patients with primary insomnia,\u201d Michelson said in a statement.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources, and they are sorely needed.", "answer": 0}, {"article": "\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed. It is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that the DAWN trial was funded by\u00a0Stryker Neuroendovascular. What it did not mention is that Stryker is a company that produces medical devices, and their device for clot removal was the only one used in the trial. Presumably, the good results from this trial will lead to an uptick in their product sales. Indeed, the news release from Stryker contains a lot more information about the specific product compared to this news release.\nWhile many journalists reading the release will understand who Stryker is and why this represents a conflict of interest, consumers reading a reposted version of the release may not have that context. For their benefit, it would be better to spell things out directly.", "answer": 1}, {"article": "The National Institute on Deafness and Other Communication Disorders estimates that 26 million Americans between the ages of 20 and 69 have high-frequency hearing loss. While 2 percent of adults aged 45 to 54 have disabling hearing loss, the rate increases to 8.5 percent for adults aged 55 to 64. Nearly 25 percent of those ages 65 to 74 and 50 percent of those who are 75 and older have disabling hearing loss.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\n\u201cOur clinical trial participants were overwhelmingly receptive to this new technology,\u201d Pillsbury said. \u201cThe technology is remarkable and so were the results.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release needed information about funding sources for the clinical trials. In addition, the release does not explain the quoted source\u2019s relationship to the study (although it is implied that he is helping to lead it).", "answer": 0}, {"article": "\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\u2022 select an item from our site index below\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources do not appear to have conflicts of interest, and none are noted. The CDC and VP of Pediatric AIDS Foundation seem to be balanced sources without ties to pharmaceutical companies. How the nevirapine studies are funded would be good to note.", "answer": 1}, {"article": "Most states with medical marijuana allow it for a list of qualifying conditions. Getting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\nThe findings in the Journal of Pain study that found chronic pain sufferers reduced their opioid use when using medical pot were limited because participants self-reported the data.\nThe research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though. Many medical professionals say there's not enough evidence for them to confidently prescribe it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0sourcing is a strong point for the story. Also,\u00a0there are no apparent conflicts of interest.", "answer": 1}, {"article": "After three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity. After six months, this proportion had increased to more than half of the women in this group (58 percent). Only 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks. Women in the acupressure group also used less pain medication than women in the control group and reported lower levels of pain overall.\n\"Initially, we simply wanted to conduct a study on the use of self-care techniques for menstrual pain. However, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics. The app helped participants to apply simple self-acupressure techniques to three different acupressure points.\n\"We were surprised to see that, after six months, two thirds of participants continued to use self-acupressure. So far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics. He adds: \"We were able to show that apps can be evaluated in a clinical trial setting. However, despite our experience with conventional clinical trials, there was a lot for us to learn - something we found both exciting and eye-opening.\" The app Luna has recently been updated and optimized for use with iOS.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say how the research was funded. The last line of the release notes the trade name of the app used in the study but not the developer.", "answer": 0}, {"article": "While most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age. Breast cancer treatments that have shown the best results for for disease free survival include chemotherapy, hormonal therapy, or both. For younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility. While many women choose to preserve the option of having children by storing eggs before cancer treatment, the process can be costly and difficult.\nItalian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause. Patients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs. The researchers followed the women for one year after they had finished chemotherapy.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients. The results are published in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited an editorial that accompanied the journal article.\u00a0 However, there was no indication of potential conflicts or lack of conflicts of interest, despite disclosures stated in the journal article.", "answer": 0}, {"article": "Kaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression. Six of the 10 said it represented a \u201creasonable\u201d value for its cost; four saw it as a low value. (The same panel voted 9 to 6 that rTMS\u2019s health benefit was equal to that of ECT.) A similar coverage decision proposal is being considered by the Medicare office serving the Washington region.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story represents both sides of this debate fairly, with the perspective of advocates from the device industry balanced against that of insurer-affiliated skeptics who say the evidence is weak. The story failed to clear the bar, however, when reporting comments from a researcher at Brown University who has conducted studies of rTMS. Although her comments are cautious and raise important questions about the treatment, the story did not disclose that she has been a consultant to, and received grant support from, rTMS device manufacturers (as indicated in this slide set from a recent presentation). It would have been nice to hear from an expert with no meaningful financial stake in this issue.", "answer": 0}, {"article": "About Carolinas HealthCare System Carolinas HealthCare System (carolinashealthcare.org), one of the nation's leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs throughout North and South Carolina. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Carolinas HealthCare System works to enhance the overall health and wellbeing of its communities through high quality patient care, education and research programs, and numerous collaborative partnerships and initiatives.\n\"Whole brain radiation patients also reported worse quality of life compared with patients who only received the focused radiation,\" adds Dr. Burri. \"Interestingly, the data showed that the addition of whole brain radiation produced no improvement in survival.\"\nDrs. Asher and Burri emphasize that the real importance of this study is its potential to make us think differently about what really matters in cancer therapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is not identified in the release. The release also makes no mention of conflicts of interest, but the journal article disclosure section notes only that one of the authors (not mentioned in the release) receives some industry funding.", "answer": 0}, {"article": "Another 22% reported only a little improvement, with pain persisting. And 7% had no improvement or their pain got worse. A few patients resorted to back surgery.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients. But a back pain specialist who spoke to WebMD says that further research is needed.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD. Before the treatment, patients had tried everything without success and were considering an operation, he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a spokesman for the American Academy of Orthopedic Surgeons and it is implied but not stated that this person was not associated with the study. The spokesman provided important context.", "answer": 1}, {"article": "Three studies looked at herbal supplements. One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote. \"Additional replications are needed before firm conclusions can be drawn.\"\nFennel, an intestinal \"antispasmodic,\" may increase the speed at which food moves through the intestine, Brown said. This may help if the underlying cause of colic is cramping or discomfort due to an immature digestive tract, although that is just a theory, Brown added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tapped two independent experts: Dr. Andrew Adesman, chief, developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children\u2019s Medical Center of New York and\u00a0Dr. Ari Brown, an Austin pediatrician and co-author of\u00a0Baby 411. Both provided good context and words of caution for concerned parents.", "answer": 1}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss. About 7.7 million Americans have diabetic retinopathy. Of these, about 750,000 have DME. The NEI provides information about diabetic eye disease at http://www.nei.nih.gov/health/diabetic. View an NEI video about how diabetic retinopathy can be detected through a comprehensive dilated eye exam at http://youtu.be/sQ-0RkPu35o.\n\u201cThis rigorous trial confirms that Eylea, Avastin, and Lucentis are all effective treatments for diabetic macular edema,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D. \u201cEye care providers and patients can have confidence in all three drugs.\u201d\n\u201cThis important study would not have happened without funding from the National Institutes of Health and the cooperation of two competing companies,\u201d said Adam R. Glassman, M.S., principal investigator of the DRCR.Net Coordinating Center at the Jaeb Center for Health Research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly spells out that the trial was funded by the National Eye Institute, part of the National Institutes of Health. It further states that two drug companies provided their drugs for the trial.", "answer": 1}, {"article": "\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\u201cFunding from NIH is helping the optometry world make significant strides in understanding the cause and treatment of dry eye,\u201d Nichols said. \u201cWe still have a long way to go, but prevention and early detection are major goals. There is hope for dry eye patients worldwide.\u201d\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release acknowledges that the person quoted was doing work for Shire plc, the company that makes the product. The release was correct to include this funder as a potential conflict of interest. It would also have been good to note that study was conducted by by the UAB Center for Translational Research.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men. The National Cancer Institute estimates 241,740 new cases of prostate cancer this year in the U.S. and 28,170 deaths.\nThe new study, designed as a proof-of-concept study, involved just 41 men. Doctors used MRI and mapping biopsies to locate the cancerous tissues. They then focused high-energy sound waves on the affected area, causing the cancer cells to heat up to around 80\u00b0C, which kills the cells. None of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections. Overall, about 95% of the men were cancer-free after a full year following the trial.\n\u201cThe signal from this study is quite strong,\u201d study author Hashim Ahmed, a urologist at the University College London, told Bloomberg. \u201cWhen you look at the current standard of care, there\u2019s a 1-in-3, or 1-in-2 chance of having the perfect outcome. In this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted \u2013 only the lead researcher.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story. Direct citations come from two sources \u2013 both of whom are researchers involved in the study. The story does bring up the fact that KEEPS was funded by the Kronos Longevity Research Institute, a nonprofit organization in Phoenix. No conflicts of interests are listed. But it\u2019s not clear who actually paid for this substantial study. A non-profit institute does not mean that it is free of pharmaceutical industry support.\u00a0The organization Kronos institiute is supported by the nonprofit \u201cAurora Foundation\u201d, which gave $34 million for this study according to Indiana University Philanthropy website. Who are they?", "answer": 0}, {"article": "Alzheimer\u2019s disease, the most common form of dementia, can be fully cured with an anti-inflammatory drug commonly used for period pain, a new research by the University of Manchester shows. Currently, no drug medications can successfully treat chronic neurodegenerative disease, but certain medicines can help alleviate symptoms or slow down the progression.\nResearchers, who conducted the study on mice, found that mefenamic acid \u2014 a common Non-Steroidal Anti Inflammatory Drug (NSAID) used to relieve menstrual pain \u2014 can completely reverse memory loss and brain inflammation that are hallmark changes of Alzheimer\u2019s, which currently affects over five million Americans.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse. Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0are no\u00a0independent sources in the story.", "answer": 0}, {"article": "Epilepsy is a neurological disorder in which the brain's normal electrical activity is temporarily disrupted, leading to a seizure. Seizures can be obvious, causing unconsciousness or convulsions, but often they trigger subtler changes in a person's perceptions or behavior -- like a short staring spell, confusion or an altered sense of taste or smell.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nIf people know a seizure is coming, Cook said, they can avoid driving or swimming that day, for example. They might also be able to adjust their medication use.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert source contributed important cautious perspectives.\u00a0 The fact that the study was funded by the device manufacturer and that several of the authoring researchers work for the company was disclosed.", "answer": 1}, {"article": "In the top three most effective formulations of ECP, 90.6% (29 of 32) of patients had a rating of excellent or good. With ColonaryConcepts' lead formulation, 93.3% (14 of 15) of patients had a rating of excellent or good, with 40 of 45 colon segments rated as excellent or good on the Ottawa scale. For the comparator products, 85.7% (12 of 14) had a rating of excellent or good. There were no serious adverse events across any of the treatment groups. The proportion of patients reporting being satisfied or extremely satisfied with the experience of using the lead ECP formulation was nearly double that for those using the standard preps, 64.3% versus 33.3%.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\nResults from the randomized, single-blind study will be presented today at the American College of Gastroenterology 2016 Annual Scientific Meeting, being held in Las Vegas, NV, by principal investigator, Douglas K. Rex, M.D., Distinguished Professor of Medicine, Indiana University School of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The developer of this prep, ColonaryConcepts, LLC, is clearly identified in the news release, and a couple of other sources are also clearly linked to the company.\u00a0 However, one source, identified as the principal investigator for the study, is described in a conference abstract as a consultant for the company, but that was not made clear in the release.", "answer": 0}, {"article": "About three-fourths of the U.S. population aged 75 and older live with hypertension, a leading contributor to cardiovascular disease and death. Although the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population. One group has recommended a target blood pressure of 160 mm Hg for persons aged 80 or older, while another recommended a target of 150 mm Hg for adults aged 60 or older. Other experts have supported keeping the standard treatment goal at 140 mm Hg.\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent. This lower blood pressure goal also reduced the risk of death among this group by 32 percent, compared to a target systolic pressure of 140 mm Hg. The benefits of a more aggressive blood pressure intervention occurred in both frail (individuals with several impairments or disorders) and non-frail older participants, the researchers note.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While this release does identify the main funding sources for the trial, it fails to mention any potential conflicts of interest, even though the paper itself discloses that three of the authors had numerous financial links to pharmaceutical firms.", "answer": 0}, {"article": "Designed by Epic Sciences and based on results from multiple studies led by Memorial Sloan Kettering Cancer Center, the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test is the first and only liquid biopsy test of its kind that can potentially prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC) by helping their physician identify the most effective treatment. Through a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind\u00ae platform to accurately identify patients who are resistant to androgen receptor (AR)-targeted therapies and who should instead switch to chemotherapy. The Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test will be performed by Epic Sciences at its centralized, CLIA-certified laboratory in San Diego and offered exclusively by Genomic Health. To learn more about the Oncotype DX AR-V7 Nucleus Detest test, visit www.OncotypeIQ.com and watch this video to learn more.\n\"This liquid biopsy test addresses a critical unmet need at a decision point in management to predict and select the therapy that is most likely to extend a patient's life,\" said Howard Scher, M.D., who led the study and is the co-chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at MSK. \"During the treatment of metastatic prostate cancer, physicians will now be able to use AR-V7 status to determine when a patient's cancer has become resistant to androgen receptor directed therapy and will respond better to chemotherapy, enabling the patient to live longer.\"\n\"We developed this test specifically to address a significant clinical question in metastatic prostate cancer that previously had no clear answer: which treatment should be pursued next? This question weighs heavily on doctors and patients, but now, with the Oncotype DX AR-V7 test, we can provide them the confidence to know whether continuing with hormonal therapy or switching to chemotherapy will result in better survival outcomes,\" said Ryan Dittamore, chief of medical innovation at Epic Sciences and a co-author on the study. \"In addition, the survival benefit gained through the utilization of our AR-V7 test could make the test as valuable to a patient's outcome as a blockbuster cancer drug.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that Epic Sciences \u201cdesigned\u201d the test and that different research institutions led research studies on the blood test. The release could have been much more transparent about who funded the research.\nThe study didn\u2019t mention all of the researchers\u2019 industry ties, but it did mention that some of the researchers are employed by Epic Sciences, the developer of the test.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful. Sufferers can spend years and hundreds of dollars trying to clear the infection with drugs, topical treatments and home remedies, sometimes to no avail. It tends to be a cosmetic issue for the younger set and a pain issue for older folks.\nResearch done by PinPointe, which is based in Chico, Calif., identified more than 100 organisms, including fungi, yeast, mold and bacteria, that work together to cause toenail fungus.\nKominsky has treated 400 to 500 patients with the PinPointe laser. Compared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple sources quoted and some are critical of laser treatment, but, on balance we thought too much weight was given to a conflicted physician and a conflicted study. The physician who is quoted the most frequently is heavily selling these treatments. And the only study presented as proof of the laser treatment\u2019s efficacy is also the only study being promoted on the website of the company highlighted in the story, PinPointe USA. The author of that study is\u00a0the head of\u00a0PinPointe\u2019s Advisory Panel. http://pinpointefootlaser.com/news-and-events/press-releases/dr-adam-landsman-appointed-head-of-pinpointe-usas-advisory-panel\u00a0This should have been noted in the story.", "answer": 0}, {"article": "\u2022 If you have any question or request regarding interview opportunities, please contact:\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain. \"This message should be relayed by general practitioners, who play a key and essential role in promoting exercise behaviour in the elderly,\" he said. \"Even a little is good, and more may be better.\"\nNow, a study in a French cohort of more than 1000 elderly subjects (the PROOF study) has found a negative correlation between their level of physical activity and risk of all-cause death, suggesting that in the elderly (as in other population groups) the risk of death decreases with greater and more regular exercise.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any funding sources for the study or potential conflicts of interest.", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not seek an outside perspective. The competing USA Today story quoted 3 other experts who provided valuable context.", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\nMore intensive treatment for patients with acute kidney injury did not bring better results in a large randomized, controlled clinical trial sponsored by the U.S. Department of Veterans Affairs and the National Institutes of Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no evidence that the newspaper interviewed anyone for this story.\u00a0 The perspectives of the study\u2019s lead author and of the editorial writer both appear to be gleaned directly from the New England Journal of Medicine. \nThe story would have been improved by including comments from interviews with clinicians about what this information means to people who may need to deal with acute kidney injury in the future.\u00a0", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels. Rising levels of PSA (prostate-specific antigen) are a sign that prostate cancer may be getting worse.\nAt the start of the study, the men's PSA levels were doubling every 12 months. After six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The input from the Sloan-Kettering expert saved the story.\nAnd the story did disclose that the lead author \u201cis an unpaid consultant to POM Wonderful, which makes both the pomegranate capsules and the juice used in the earlier study.\u201d", "answer": 1}, {"article": "For more about prostate cancer, visit the American Cancer Society.\nHollis reported that in some cases the tumor shrank and in others the cancer went away. However, the study was small, and results from a larger trial aren't expected for several years, he added.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the chief of radiation oncology at Brigham and Women\u2019s Hospital in Boston in the strongest possible way concluding that the study was too small to establish any value of vitamin D supplements and prostate cancer prevention or therapy. There is no indication that the vitamin supplement industry had any role in the research. However, the article might have pointed out that the researcher, Bruce Hollis, has been conducting studies about the benefits of vitamin D for decades and is a widely quoted expert on the potential benefits of the vitamin in disease prevention. Hollis was quoted elsewhere on this study saying that \u201cdoctors should be recommending vitamin D\u2083 for men with low-grade prostate cancer,\u201d and we\u2019re glad to see that HealthDay did not pass along those overly enthusiastic comments.", "answer": 1}, {"article": "Also, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract. However, a similar approach might work for some other mutations.\nWhile steroids, which reduce inflammation, can slow progression of the disease, they have undesirable side effects. Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nOne possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on a pre-abstract release of information from the company.\u00a0 The study\u2019s principal investigator, the company CEO and parents of children enrolled in the study are the only sources quoted in the story.\u00a0 We think that an independent expert should have been quoted.", "answer": 0}, {"article": "She recommended that older adults get regular eye checkups, and have any vision symptoms checked out and treated promptly.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable. Even incurable causes of age-related vision loss such as glaucoma and age-related macular degeneration \u201care highly treatable, so we can reduce the amount of vision loss that people suffer from if they\u2019re detected early.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study was funded by the National Eye Institute and the Jane Kroger Fund. It would have been beneficial to include the funding sources in the story. However, omitting the name of a government or non-profit funder does not merit a Not Satisfactory rating.", "answer": 1}, {"article": "Controlled breathing may also affect the immune system. Researchers at the Medical University of South Carolina divided a group of 20 healthy adults into two groups. One group was instructed to do two sets of 10-minute breathing exercises, while the other group was told to read a text of their choice for 20 minutes. The subjects\u2019 saliva was tested at various intervals during the exercise. The researchers found that the breathing exercise group\u2019s saliva had significantly lower levels of three cytokines that are associated with inflammation and stress. The findings were published in the journal BMC Complementary and Alternative Medicine in August.\n\u201cThe findings were exciting,\u201d she said. \u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased. The research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas. While the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the biggest shortcoming of the article: All of those quoted have research and/or books to promote. The story could have used some sources who have a broader view of therapeutic approaches to stress.", "answer": 0}, {"article": "Dr. Smith does not advocate that strategy, saying that the stool test can have false positives from things like red meat or broccoli that have nothing to do with colon cancer. He worries that frequent stool tests will lead to frequent false alarms and frequent colonoscopies without making much of a dent in the colon cancer death rate.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said. That usually means taking half of the laxative the night before the screening test and the rest in the morning, something that often is not done, he added, but that he and others recommend.\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Women whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent. The women whose cancers were detected by mammograms were less likely to be given chemotherapy.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nDr. Virginia Moyer, chair of the U.S. Preventive Services Task Force and a professor of pediatrics at Baylor College of Medicine, reviewed the study. \"The findings make sense,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did interview the chair of the U.S. Preventive Services Task Force (USPSTF).", "answer": 1}, {"article": "Dr. Gurpreet Singh Ranger from Upper River Valley Hospital, Waterville, New Brunswick and Dalhousie Medical School, in Halifax, Nova Scotia, Canada, agreed with Dr. Friis.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nEarlier studies had suggested that aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may help protect against colorectal cancer, but it wasn\u2019t clear how much had to be taken, and for how long, to achieve those benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comment from Dr. Gurpreet Singh-Ranger, who apparently was not involved with the study, so we\u2019ll give it a pass. The story\u00a0would have been stronger had it told the reader what made him an authority on the topic.", "answer": 1}, {"article": "\"So this is the cyclotron itself, this is a 200-ton piece of machinery that accelerates the protons to 230 million electron volts,\" Metz said.\n\"It's a real delight to be able to offer patients proton therapy you see that during the treatment they have less side effects,\" said Jay Loeffler, the chair of radiation oncology at Massachusetts General Hospital Cancer Center.\n\"There is no good evidence, medical evidence that it is better than the current state of the art intensity modular radiation therapy,\" Stock said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women. Non-small cell lung cancer constitutes about 85-90% of lung cancer cases.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited besides the ACS statistics on lung cancer. Any story that allows a researcher to make bold claims such as that this research \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide\" demands an independent perspective.\u00a0 ", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotations in the story, only reporting on what appeared in the journal Menopause.\u00a0 There are no comments from independent sources and also no mention of conflicts of interest.", "answer": 0}]